BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wong VW, Wong GL, Choi PC, Chan AW, Li MK, Chan HY, Chim AM, Yu J, Sung JJ, Chan HL. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut 2010;59:969-74. [PMID: 20581244 DOI: 10.1136/gut.2009.205088] [Cited by in Crossref: 400] [Cited by in F6Publishing: 360] [Article Influence: 36.4] [Reference Citation Analysis]
Number Citing Articles
1 Heydari M, Cornide-Petronio ME, Jiménez-Castro MB, Peralta C. Data on Adiponectin from 2010 to 2020: Therapeutic Target and Prognostic Factor for Liver Diseases? Int J Mol Sci 2020;21:E5242. [PMID: 32718097 DOI: 10.3390/ijms21155242] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
2 Kim Y, Chang Y, Cho YK, Ahn J, Shin H, Ryu S. Metabolically healthy versus unhealthy obesity and risk of fibrosis progression in non‐alcoholic fatty liver disease. Liver Int 2019;39:1884-94. [DOI: 10.1111/liv.14184] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
3 Mells JE, Fu PP, Kumar P, Smith T, Karpen SJ, Anania FA. Saturated fat and cholesterol are critical to inducing murine metabolic syndrome with robust nonalcoholic steatohepatitis. J Nutr Biochem 2015;26:285-92. [PMID: 25577467 DOI: 10.1016/j.jnutbio.2014.11.002] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 6.0] [Reference Citation Analysis]
4 Hanson A, Wilhelmsen D, DiStefano JK. The Role of Long Non-Coding RNAs (lncRNAs) in the Development and Progression of Fibrosis Associated with Nonalcoholic Fatty Liver Disease (NAFLD). Noncoding RNA 2018;4:E18. [PMID: 30134610 DOI: 10.3390/ncrna4030018] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
5 Sharma P, Arora A. Clinical presentation of alcoholic liver disease and non-alcoholic fatty liver disease: spectrum and diagnosis. Transl Gastroenterol Hepatol 2020;5:19. [PMID: 32258523 DOI: 10.21037/tgh.2019.10.02] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
6 Stål P. Liver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance. World J Gastroenterol 2015;21:11077-87. [PMID: 26494963 DOI: 10.3748/wjg.v21.i39.11077] [Cited by in CrossRef: 69] [Cited by in F6Publishing: 60] [Article Influence: 13.8] [Reference Citation Analysis]
7 Xu Z, Zhang X, Lau J, Yu J. C-X-C motif chemokine 10 in non-alcoholic steatohepatitis: role as a pro-inflammatory factor and clinical implication. Expert Rev Mol Med 2016;18:e16. [PMID: 27669973 DOI: 10.1017/erm.2016.16] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
8 Seko Y, Yano K, Takahashi A, Okishio S, Kataoka S, Okuda K, Umemura A, Yamaguchi K, Moriguchi M, Tanaka S, Itoh Y. The Appropriate Opportunity for Evaluating Liver Fibrosis by Using the FIB-4 Index in Patients with Nonalcoholic Fatty Liver Disease in Japan. Diagnostics (Basel) 2020;10:E842. [PMID: 33086582 DOI: 10.3390/diagnostics10100842] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Wong GL, Wong VW. Commentary: coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis B - authors' reply. Aliment Pharmacol Ther 2014;39:1236-7. [PMID: 24735138 DOI: 10.1111/apt.12714] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
10 Lang S, Farowski F, Martin A, Wisplinghoff H, Vehreschild MJGT, Krawczyk M, Nowag A, Kretzschmar A, Scholz C, Kasper P, Roderburg C, Lammert F, Goeser T, Steffen HM, Demir M. Prediction of advanced fibrosis in non-alcoholic fatty liver disease using gut microbiota-based approaches compared with simple non-invasive tools. Sci Rep 2020;10:9385. [PMID: 32523101 DOI: 10.1038/s41598-020-66241-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
11 Koeckerling D, Tomlinson JW, Cobbold JF. Fighting liver fat. Endocr Connect 2020;9:R173-86. [PMID: 32621584 DOI: 10.1530/EC-20-0174] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
12 Mantovani A, Zaza G, Byrne CD, Lonardo A, Zoppini G, Bonora E, Targher G. Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: A systematic review and meta-analysis. Metabolism. 2018;79:64-76. [PMID: 29137912 DOI: 10.1016/j.metabol.2017.11.003] [Cited by in Crossref: 131] [Cited by in F6Publishing: 107] [Article Influence: 32.8] [Reference Citation Analysis]
13 Demir M, Lang S, Steffen HM. Nonalcoholic fatty liver disease - current status and future directions. J Dig Dis 2015;16:541-57. [PMID: 26406351 DOI: 10.1111/1751-2980.12291] [Cited by in Crossref: 58] [Cited by in F6Publishing: 49] [Article Influence: 11.6] [Reference Citation Analysis]
14 Pezeshki A, Safi S, Feizi A, Askari G, Karami F. The Effect of Green Tea Extract Supplementation on Liver Enzymes in Patients with Nonalcoholic Fatty Liver Disease. Int J Prev Med 2016;7:28. [PMID: 26955458 DOI: 10.4103/2008-7802.173051] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 7.6] [Reference Citation Analysis]
15 Polyzos SA, Kountouras J, Mantzoros CS. Leptin in nonalcoholic fatty liver disease: a narrative review. Metabolism. 2015;64:60-78. [PMID: 25456097 DOI: 10.1016/j.metabol.2014.10.012] [Cited by in Crossref: 108] [Cited by in F6Publishing: 90] [Article Influence: 15.4] [Reference Citation Analysis]
16 Dichtel LE, Corey KE, Misdraji J, Bredella MA, Schorr M, Osganian SA, Young BJ, Sung JC, Miller KK. The Association Between IGF-1 Levels and the Histologic Severity of Nonalcoholic Fatty Liver Disease. Clin Transl Gastroenterol 2017;8:e217. [PMID: 28125073 DOI: 10.1038/ctg.2016.72] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 7.0] [Reference Citation Analysis]
17 Wu T, Ye J, Gong X, Li X, Shao C, Li F, Lin Y, Ma Q, Mai W, Wang W, Feng ST, Zhong B. Apolipoproteins and liver parameters optimize cardiovascular disease risk-stratification in nonalcoholic fatty liver disease. Dig Liver Dis 2021:S1590-8658(21)00055-4. [PMID: 33744170 DOI: 10.1016/j.dld.2021.02.003] [Reference Citation Analysis]
18 Chatzigeorgiou A, Chavakis T. Immune Cells and Metabolism. In: Herzig S, editor. Metabolic Control. Cham: Springer International Publishing; 2016. pp. 221-49. [DOI: 10.1007/164_2015_8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
19 Hu D, Wang H, Wang H, Wang Y, Wan X, Yan W, Luo X, Ning Q. Non-alcoholic hepatic steatosis attenuates hepatitis B virus replication in an HBV-immunocompetent mouse model. Hepatol Int 2018;12:438-46. [DOI: 10.1007/s12072-018-9877-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 5.7] [Reference Citation Analysis]
20 Schneck AS, Anty R, Patouraux S, Bonnafous S, Rousseau D, Lebeaupin C, Bailly-Maitre B, Sans A, Tran A, Gugenheim J, Iannelli A, Gual P. Roux-En Y Gastric Bypass Results in Long-Term Remission of Hepatocyte Apoptosis and Hepatic Histological Features of Non-alcoholic Steatohepatitis. Front Physiol. 2016;7:344. [PMID: 27594839 DOI: 10.3389/fphys.2016.00344] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
21 Shen J, Wong GL, Chan HL, Chan RS, Chan H, Chu WC, Cheung BH, Yeung DK, Li LS, Sea MM, Woo J, Wong VW. PNPLA3 gene polymorphism and response to lifestyle modification in patients with nonalcoholic fatty liver disease: PNPLA3 and lifestyle modification. J Gastroenterol Hepatol 2015;30:139-46. [DOI: 10.1111/jgh.12656] [Cited by in Crossref: 83] [Cited by in F6Publishing: 73] [Article Influence: 11.9] [Reference Citation Analysis]
22 Mencin AA, Lavine JE. Advances in pediatric nonalcoholic fatty liver disease. Pediatr Clin North Am. 2011;58:1375-1392, x. [PMID: 22093857 DOI: 10.1016/j.pcl.2011.09.005] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 3.1] [Reference Citation Analysis]
23 Petrick A, Benotti P, Wood GC, Still CD, Strodel WE, Gabrielsen J, Rolston D, Chu X, Argyropoulos G, Ibele A, Gerhard GS. Utility of Ultrasound, Transaminases, and Visual Inspection to Assess Nonalcoholic Fatty Liver Disease in Bariatric Surgery Patients. Obes Surg 2015;25:2368-75. [PMID: 26003548 DOI: 10.1007/s11695-015-1707-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 5.4] [Reference Citation Analysis]
24 Tanajewski L, Harris R, Harman DJ, Aithal GP, Card TR, Gkountouras G, Berdunov V, Guha IN, Elliott RA. Economic evaluation of a community-based diagnostic pathway to stratify adults for non-alcoholic fatty liver disease: a Markov model informed by a feasibility study. BMJ Open. 2017;7:e015659. [PMID: 28679676 DOI: 10.1136/bmjopen-2016-015659] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
25 Zhao L, Westerhoff M, Pai RK, Choi WT, Gao ZH, Hart J. Centrilobular ductular reaction correlates with fibrosis stage and fibrosis progression in non-alcoholic steatohepatitis. Mod Pathol 2018;31:150-9. [PMID: 28862262 DOI: 10.1038/modpathol.2017.115] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
26 Sullivan S, Kirk EP, Mittendorfer B, Patterson BW, Klein S. Randomized trial of exercise effect on intrahepatic triglyceride content and lipid kinetics in nonalcoholic fatty liver disease. Hepatology. 2012;55:1738-1745. [PMID: 22213436 DOI: 10.1002/hep.25548] [Cited by in Crossref: 162] [Cited by in F6Publishing: 138] [Article Influence: 18.0] [Reference Citation Analysis]
27 Xu C, Yu C, Ma H, Xu L, Miao M, Li Y. Prevalence and risk factors for the development of nonalcoholic fatty liver disease in a nonobese Chinese population: the Zhejiang Zhenhai Study. Am J Gastroenterol. 2013;108:1299-1304. [PMID: 23567356 DOI: 10.1038/ajg.2013.104] [Cited by in Crossref: 97] [Cited by in F6Publishing: 88] [Article Influence: 12.1] [Reference Citation Analysis]
28 Caballería L, Arteaga I, Pera G, Rodríguez L, Alumà A, Auladell MA, Torán P. [Risk factors associated with non-alcoholic fatty liver disease: a case-control study]. Med Clin (Barc) 2013;141:233-9. [PMID: 23601740 DOI: 10.1016/j.medcli.2012.11.034] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
29 Qian LL, Wu L, Zhang L, Zhang J, Zhou J, Li YH, Fang QC, Li HT, Jia WP. Serum biomarkers combined with ultrasonography for early diagnosis of non-alcoholic fatty liver disease confirmed by magnetic resonance spectroscopy. Acta Pharmacol Sin 2020;41:554-60. [PMID: 31776449 DOI: 10.1038/s41401-019-0321-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
30 Larner DP, Morgan SA, Gathercole LL, Doig CL, Guest P, Weston C, Hazeldine J, Tomlinson JW, Stewart PM, Lavery GG. Male 11β-HSD1 Knockout Mice Fed Trans-Fats and Fructose Are Not Protected From Metabolic Syndrome or Nonalcoholic Fatty Liver Disease. Endocrinology 2016;157:3493-504. [PMID: 27384305 DOI: 10.1210/en.2016-1357] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
31 Wang Y, Hou J. Fibrosis assessment: impact on current management of chronic liver disease and application of quantitative invasive tools. Hepatol Int 2016;10:448-61. [DOI: 10.1007/s12072-015-9695-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
32 Musso G. The Finnish Diabetes Risk Score (FINDRISC) and other non-invasive scores for screening of hepatic steatosis and associated cardiometabolic risk. Annals of Medicine 2011;43:413-7. [DOI: 10.3109/07853890.2011.579152] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
33 Siebers N, Palmer M, Silberg DG, Jennings L, Bliss C, Martin PT. Absorption, Distribution, Metabolism, and Excretion of [14C]-Volixibat in Healthy Men: Phase 1 Open-Label Study. Eur J Drug Metab Pharmacokinet 2018;43:91-101. [PMID: 28702877 DOI: 10.1007/s13318-017-0429-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
34 Wu Z, Cheng Z, Yi Z, Xie M, Zeng H, Lu L, Xu X, Shen J. Assessment of Nonalcoholic Fatty Liver Disease in Rats Using Quantitative Dynamic Contrast‐Enhanced MRI. J Magn Reson Imaging 2017;45:1485-93. [DOI: 10.1002/jmri.25455] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
35 Dyson JK, Anstee QM, McPherson S. Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging. Frontline Gastroenterol 2014;5:211-8. [PMID: 25018867 DOI: 10.1136/flgastro-2013-100403] [Cited by in Crossref: 135] [Cited by in F6Publishing: 118] [Article Influence: 16.9] [Reference Citation Analysis]
36 Cazzo E, Jimenez LS, Pareja JC, Chaim EA. Effect of Roux-en-Y gastric bypass on nonalcoholic fatty liver disease evaluated through NAFLD fibrosis score: a prospective study. Obes Surg. 2015;25:982-985. [PMID: 25381118 DOI: 10.1007/s11695-014-1489-2] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 5.5] [Reference Citation Analysis]
37 Michopoulos S, Chouzouri VI, Manios ED, Grapsa E, Antoniou Z, Papadimitriou CA, Zakopoulos N, Dimopoulos AM. Untreated newly diagnosed essential hypertension is associated with nonalcoholic fatty liver disease in a population of a hypertensive center. Clin Exp Gastroenterol 2016;9:1-9. [PMID: 26834493 DOI: 10.2147/CEG.S92714] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
38 Tuleta I, Frangogiannis NG. Diabetic fibrosis. Biochim Biophys Acta Mol Basis Dis 2021;1867:166044. [PMID: 33378699 DOI: 10.1016/j.bbadis.2020.166044] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
39 Henry ZH, Argo CK. How to Identify the Patient with Nonalcoholic Steatohepatitis Who Will Progress to Cirrhosis. Gastroenterology Clinics of North America 2020;49:45-62. [DOI: 10.1016/j.gtc.2019.09.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Schneier AT, Citti CC, Dieterich DT. Management and diagnosis of fatty liver disease. Expert Rev Gastroenterol Hepatol. 2015;9:671-683. [PMID: 25716275 DOI: 10.1586/17474124.2015.1003209] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
41 Kumar A, Shalimar, Walia GK, Gupta V, Sachdeva MP. Genetics of nonalcoholic fatty liver disease in Asian populations. J Genet 2019;98. [DOI: 10.1007/s12041-019-1071-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
42 Wai JW, Fu C, Wong VW. Confounding factors of non-invasive tests for nonalcoholic fatty liver disease. J Gastroenterol 2020;55:731-41. [PMID: 32451628 DOI: 10.1007/s00535-020-01686-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
43 Pandit H, Tinney JP, Li Y, Cui G, Li S, Keller BB, Martin RC. Utilizing Contrast-Enhanced Ultrasound Imaging for Evaluating Fatty Liver Disease Progression in Pre-clinical Mouse Models. Ultrasound in Medicine & Biology 2019;45:549-57. [DOI: 10.1016/j.ultrasmedbio.2018.10.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
44 Tran A, Gual P. Non-alcoholic steatohepatitis in morbidly obese patients. Clin Res Hepatol Gastroenterol. 2013;37:17-29. [PMID: 23347840 DOI: 10.1016/j.clinre.2012.07.005] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
45 Huang X, Lee F, Teng Y, Lingam CB, Chen Z, Sun M, Song Z, Balachander GM, Leo HL, Guo Q, Shah I, Yu H. Sequential drug delivery for liver diseases. Adv Drug Deliv Rev 2019;149-150:72-84. [PMID: 31734169 DOI: 10.1016/j.addr.2019.11.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
46 Fukuyama Y, Tokuhara D, Sekine S, Kataoka K, Markham JD, Irwin AR, Moon GH, Tokuhara Y, Fujihashi K, Davydova J, Yamamoto M, Gilbert RS, Fujihashi K. Notch-ligand expression by NALT dendritic cells regulates mucosal Th1- and Th2-type responses. Biochem Biophys Res Commun 2012;418:6-11. [PMID: 22200492 DOI: 10.1016/j.bbrc.2011.12.046] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
47 Goh GB, McCullough AJ. Natural History of Nonalcoholic Fatty Liver Disease. Dig Dis Sci 2016;61:1226-33. [PMID: 27003142 DOI: 10.1007/s10620-016-4095-4] [Cited by in Crossref: 67] [Cited by in F6Publishing: 56] [Article Influence: 13.4] [Reference Citation Analysis]
48 Paglialunga S, Dehn CA. Clinical assessment of hepatic de novo lipogenesis in non-alcoholic fatty liver disease. Lipids Health Dis. 2016;15:159. [PMID: 27640119 DOI: 10.1186/s12944-016-0321-5] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 8.2] [Reference Citation Analysis]
49 Dulai PS, Sirlin CB, Loomba R. MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practice. J Hepatol. 2016;65:1006-1016. [PMID: 27312947 DOI: 10.1016/j.jhep.2016.06.005] [Cited by in Crossref: 176] [Cited by in F6Publishing: 152] [Article Influence: 35.2] [Reference Citation Analysis]
50 Park HJ, Lee JY, Chung MY, Park YK, Bower AM, Koo SI, Giardina C, Bruno RS. Green tea extract suppresses NFκB activation and inflammatory responses in diet-induced obese rats with nonalcoholic steatohepatitis. J Nutr. 2012;142:57-63. [PMID: 22157544 DOI: 10.3945/jn.111.148544] [Cited by in Crossref: 93] [Cited by in F6Publishing: 76] [Article Influence: 9.3] [Reference Citation Analysis]
51 Kang SH, Lee HW, Yoo JJ, Cho Y, Kim SU, Lee TH, Jang BK, Kim SG, Ahn SB, Kim H, Jun DW, Choi JI, Song DS, Kim W, Jeong SW, Kim MY, Koh H, Jeong S, Lee JW, Cho YK; Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease. Clin Mol Hepatol 2021;27:363-401. [PMID: 34154309 DOI: 10.3350/cmh.2021.0178] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 Lemoine M, Serfaty L, Cervera P, Capeau J, Ratziu V. Hepatic molecular effects of rosiglitazone in human non-alcoholic steatohepatitis suggest long-term pro-inflammatory damage. Hepatol Res 2014;44:1241-7. [PMID: 24118921 DOI: 10.1111/hepr.12244] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
53 Huang X, Xu M, Chen Y, Peng K, Huang Y, Wang P, Ding L, Lin L, Xu Y, Chen Y, Lu J, Wang W, Bi Y, Ning G. Validation of the Fatty Liver Index for Nonalcoholic Fatty Liver Disease in Middle-Aged and Elderly Chinese. Medicine (Baltimore) 2015;94:e1682. [PMID: 26448014 DOI: 10.1097/MD.0000000000001682] [Cited by in Crossref: 59] [Cited by in F6Publishing: 25] [Article Influence: 11.8] [Reference Citation Analysis]
54 Kim YS, Lee SH, Park SG, Won BY, Chun H, Cho DY, Kim MJ, Lee JE, Haam JH, Han K. Low levels of total and high-molecular-weight adiponectin may predict non-alcoholic fatty liver in Korean adults. Metabolism 2020;103:154026. [PMID: 31765666 DOI: 10.1016/j.metabol.2019.154026] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
55 Perumpail BJ, Khan MA, Yoo ER, Cholankeril G, Kim D, Ahmed A. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J Gastroenterol. 2017;23:8263-8276. [PMID: 29307986 DOI: 10.3748/wjg.v23.i47.8263] [Cited by in CrossRef: 234] [Cited by in F6Publishing: 193] [Article Influence: 78.0] [Reference Citation Analysis]
56 Shen J, Wong GL, Chan HL, Chan HY, Yeung DK, Chan RS, Chim AM, Chan AW, Choi PC, Woo J, Chu WC, Wong VW. PNPLA3 gene polymorphism accounts for fatty liver in community subjects without metabolic syndrome. Aliment Pharmacol Ther. 2014;39:532-539. [PMID: 24417250 DOI: 10.1111/apt.12609] [Cited by in Crossref: 75] [Cited by in F6Publishing: 69] [Article Influence: 10.7] [Reference Citation Analysis]
57 Wong VW, Wong GL, Yeung DK, Abrigo JM, Kong AP, Chan RS, Chim AM, Shen J, Ho CS, Woo J. Fatty pancreas, insulin resistance, and β-cell function: a population study using fat-water magnetic resonance imaging. Am J Gastroenterol. 2014;109:589-597. [PMID: 24492753 DOI: 10.1038/ajg.2014.1] [Cited by in Crossref: 117] [Cited by in F6Publishing: 110] [Article Influence: 16.7] [Reference Citation Analysis]
58 Han B, Kim SM, Nam GE, Kim SH, Park SJ, Park YK, Baik HW. A Randomized, Double-Blind, Placebo-Controlled, Multi-Centered Clinical Study to Evaluate the Efficacy and Safety of Artemisia annua L. Extract for Improvement of Liver Function. Clin Nutr Res 2020;9:258-70. [PMID: 33204666 DOI: 10.7762/cnr.2020.9.4.258] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Svop Jensen V, Fledelius C, Max Wulff E, Lykkesfeldt J, Hvid H. Temporal Development of Dyslipidemia and Nonalcoholic Fatty Liver Disease (NAFLD) in Syrian Hamsters Fed a High-Fat, High-Fructose, High-Cholesterol Diet. Nutrients 2021;13:604. [PMID: 33673227 DOI: 10.3390/nu13020604] [Reference Citation Analysis]
60 Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73-84. [PMID: 26707365 DOI: 10.1002/hep.28431] [Cited by in Crossref: 3251] [Cited by in F6Publishing: 2784] [Article Influence: 650.2] [Reference Citation Analysis]
61 Li Q, Dhyani M, Grajo JR, Sirlin C, Samir AE. Current status of imaging in nonalcoholic fatty liver disease. World J Hepatol. 2018;10:530-542. [PMID: 30190781 DOI: 10.4254/wjh.v10.i8.530] [Cited by in Crossref: 75] [Cited by in F6Publishing: 60] [Article Influence: 25.0] [Reference Citation Analysis]
62 Piña-zentella RM, Rosado JL, Gallegos-corona MA, Madrigal-pérez LA, García OP, Ramos-gomez M. Lycopene Improves Diet-Mediated Recuperation in Rat Model of Nonalcoholic Fatty Liver Disease. Journal of Medicinal Food 2016;19:607-14. [DOI: 10.1089/jmf.2015.0123] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
63 Koh ZJ, Salgaonkar HP, Lee WJJ, Kim GW, Tan CH, Cheng A, Lomanto D, So JBY, Dan YY, Shabbir A. Improvement in Non-alcoholic Fatty Liver Disease Score Correlates with Weight Loss in Obese Patients Undergoing Laparoscopic Sleeve Gastrectomy: a Two-Centre Study from an Asian Cohort. Obes Surg 2019;29:862-8. [PMID: 30515622 DOI: 10.1007/s11695-018-3581-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
64 Zhang Y, Wang C, Duanmu Y, Zhang C, Zhao W, Wang L, Cheng X, Veronese N, Guglielmi G. Comparison of CT and magnetic resonance mDIXON-Quant sequence in the diagnosis of mild hepatic steatosis. Br J Radiol 2018;91:20170587. [PMID: 30028193 DOI: 10.1259/bjr.20170587] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
65 Hagström H, Elfwén O, Hultcrantz R, Stål P. Steatohepatitis Is Not Associated with an Increased Risk for Fibrosis Progression in Nonalcoholic Fatty Liver Disease. Gastroenterol Res Pract 2018;2018:1942648. [PMID: 30057598 DOI: 10.1155/2018/1942648] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
66 Kim H, Lee K, Lee KW, Yi NJ, Lee HW, Hong G, Choi Y, You T, Suh SW, Jang JJ. Histologically proven non-alcoholic fatty liver disease and clinically related factors in recipients after liver transplantation. Clin Transplant. 2014;28:521-529. [PMID: 24579874 DOI: 10.1111/ctr.12343] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 4.9] [Reference Citation Analysis]
67 Li J, Sapper TN, Mah E, Rudraiah S, Schill KE, Chitchumroonchokchai C, Moller MV, McDonald JD, Rohrer PR, Manautou JE, Bruno RS. Green tea extract provides extensive Nrf2-independent protection against lipid accumulation and NFκB pro- inflammatory responses during nonalcoholic steatohepatitis in mice fed a high-fat diet. Mol Nutr Food Res 2016;60:858-70. [PMID: 26679056 DOI: 10.1002/mnfr.201500814] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 8.4] [Reference Citation Analysis]
68 Pais R, Charlotte F, Fedchuk L, Bedossa P, Lebray P, Poynard T, Ratziu V; LIDO Study Group. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. J Hepatol. 2013;59:550-556. [PMID: 23665288 DOI: 10.1016/j.jhep.2013.04.027] [Cited by in Crossref: 277] [Cited by in F6Publishing: 243] [Article Influence: 34.6] [Reference Citation Analysis]
69 Berk PD, Verna EC. Nonalcoholic Fatty Liver Disease: Lipids and Insulin Resistance. Clin Liver Dis. 2016;20:245-262. [PMID: 27063267 DOI: 10.1016/j.cld.2015.10.007] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
70 Lensu S, Pariyani R, Mäkinen E, Yang B, Saleem W, Munukka E, Lehti M, Driuchina A, Lindén J, Tiirola M, Lahti L, Pekkala S. Prebiotic Xylo-Oligosaccharides Ameliorate High-Fat-Diet-Induced Hepatic Steatosis in Rats. Nutrients 2020;12:E3225. [PMID: 33105554 DOI: 10.3390/nu12113225] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
71 Seto WK, Fung J, Cheung KS, Mak LY, Hui RW, Liu KS, Lai CL, Yuen MF. Body-mass index is associated with fibrosis regression during long-term nucleoside analogue therapy in chronic hepatitis B. Aliment Pharmacol Ther. 2016;44:1071-1079. [PMID: 27659292 DOI: 10.1111/apt.13804] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
72 Zhang YN, Fowler KJ, Hamilton G, Cui JY, Sy EZ, Balanay M, Hooker JC, Szeverenyi N, Sirlin CB. Liver fat imaging-a clinical overview of ultrasound, CT, and MR imaging. Br J Radiol. 2018;91:20170959. [PMID: 29722568 DOI: 10.1259/bjr.20170959] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 13.7] [Reference Citation Analysis]
73 Wong VW, Wong GL. A LEAN treatment for non-alcoholic steatohepatitis. The Lancet 2016;387:628-30. [DOI: 10.1016/s0140-6736(15)00982-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
74 Hsu CS, Kao JH. An update on non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Asia. Expert Rev Gastroenterol Hepatol 2017;11:759-72. [PMID: 28613087 DOI: 10.1080/17474124.2017.1342535] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
75 Noureddin M, Zelber-Sagi S, Wilkens LR, Porcel J, Boushey CJ, Le Marchand L, Rosen HR, Setiawan VW. Diet Associations With Nonalcoholic Fatty Liver Disease in an Ethnically Diverse Population: The Multiethnic Cohort. Hepatology 2020;71:1940-52. [PMID: 31553803 DOI: 10.1002/hep.30967] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 26.0] [Reference Citation Analysis]
76 Bessone F, Razori MV, Roma MG. Molecular pathways of nonalcoholic fatty liver disease development and progression. Cell Mol Life Sci. 2019;76:99-128. [PMID: 30343320 DOI: 10.1007/s00018-018-2947-0] [Cited by in Crossref: 109] [Cited by in F6Publishing: 100] [Article Influence: 36.3] [Reference Citation Analysis]
77 Lallukka S, Sädevirta S, Kallio MT, Luukkonen PK, Zhou Y, Hakkarainen A, Lundbom N, Orho-Melander M, Yki-Järvinen H. Predictors of Liver Fat and Stiffness in Non-Alcoholic Fatty Liver Disease (NAFLD) - an 11-Year Prospective Study. Sci Rep 2017;7:14561. [PMID: 29109528 DOI: 10.1038/s41598-017-14706-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
78 Pi-Sunyer X. Changes in body composition and metabolic disease risk. Eur J Clin Nutr 2019;73:231-5. [PMID: 30275524 DOI: 10.1038/s41430-018-0320-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
79 Younossi ZM, Stepanova M, Negro F, Hallaji S, Younossi Y, Lam B, Srishord M. Nonalcoholic fatty liver disease in lean individuals in the United States. Medicine (Baltimore). 2012;91:319-327. [PMID: 23117851 DOI: 10.1097/md.0b013e3182779d49] [Cited by in Crossref: 280] [Cited by in F6Publishing: 133] [Article Influence: 35.0] [Reference Citation Analysis]
80 Xu L, Zhou J, Che J, Wang H, Yang W, Zhou W, Zhao H. Mitochondrial DNA enables AIM2 inflammasome activation and hepatocyte pyroptosis in nonalcoholic fatty liver disease. Am J Physiol Gastrointest Liver Physiol 2021;320:G1034-44. [PMID: 33728991 DOI: 10.1152/ajpgi.00431.2020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
81 Ku NO, Strnad P, Bantel H, Omary MB. Keratins: Biomarkers and modulators of apoptotic and necrotic cell death in the liver. Hepatology 2016;64:966-76. [PMID: 26853542 DOI: 10.1002/hep.28493] [Cited by in Crossref: 56] [Cited by in F6Publishing: 45] [Article Influence: 11.2] [Reference Citation Analysis]
82 Musso G, Gambino R, Tabibian JH, Ekstedt M, Kechagias S, Hamaguchi M, Hultcrantz R, Hagström H, Yoon SK, Charatcharoenwitthaya P, George J, Barrera F, Hafliðadóttir S, Björnsson ES, Armstrong MJ, Hopkins LJ, Gao X, Francque S, Verrijken A, Yilmaz Y, Lindor KD, Charlton M, Haring R, Lerch MM, Rettig R, Völzke H, Ryu S, Li G, Wong LL, Machado M, Cortez-Pinto H, Yasui K, Cassader M. Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med 2014;11:e1001680. [PMID: 25050550 DOI: 10.1371/journal.pmed.1001680] [Cited by in Crossref: 283] [Cited by in F6Publishing: 245] [Article Influence: 40.4] [Reference Citation Analysis]
83 Rodrŕguez-hernández H, Cervantes-huerta M, Rodrŕguez-moran M, Guerrero-romero F. Decrease of aminotransferase levels in obese women is related to body weight reduction, irrespective of type of diet. Annals of Hepatology 2011;10:486-92. [DOI: 10.1016/s1665-2681(19)31517-0] [Cited by in Crossref: 29] [Article Influence: 2.9] [Reference Citation Analysis]
84 Loomba R, Seguritan V, Li W, Long T, Klitgord N, Bhatt A, Dulai PS, Caussy C, Bettencourt R, Highlander SK, Jones MB, Sirlin CB, Schnabl B, Brinkac L, Schork N, Chen CH, Brenner DA, Biggs W, Yooseph S, Venter JC, Nelson KE. Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease. Cell Metab. 2017;25:1054-1062.e5. [PMID: 28467925 DOI: 10.1016/j.cmet.2017.04.001] [Cited by in Crossref: 349] [Cited by in F6Publishing: 301] [Article Influence: 116.3] [Reference Citation Analysis]
85 Kawanaka M, Nishino K, Nakamura J, Urata N, Oka T, Goto D, Suehiro M, Kawamoto H, Yamada G. Correlation between serum cytokeratin-18 and the progression or regression of non-alcoholic fatty liver disease. Annals of Hepatology 2015;14:837-44. [DOI: 10.5604/16652681.1171767] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
86 Wong VW, Chitturi S, Wong GL, Yu J, Chan HL, Farrell GC. Pathogenesis and novel treatment options for non-alcoholic steatohepatitis. Lancet Gastroenterol Hepatol 2016;1:56-67. [PMID: 28404113 DOI: 10.1016/S2468-1253(16)30011-5] [Cited by in Crossref: 91] [Cited by in F6Publishing: 29] [Article Influence: 18.2] [Reference Citation Analysis]
87 Ashtari S, Pourhoseingholi MA, Zali MR. Non-alcohol fatty liver disease in Asia: Prevention and planning. World J Hepatol. 2015;7:1788-1796. [PMID: 26167252 DOI: 10.4254/wjh.v7.i13.1788] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 5.8] [Reference Citation Analysis]
88 Papagianni M, Sofogianni A, Tziomalos K. Non-invasive methods for the diagnosis of nonalcoholic fatty liver disease. World J Hepatol 2015;7:638-48. [PMID: 25866601 DOI: 10.4254/wjh.v7.i4.638] [Cited by in Crossref: 43] [Cited by in F6Publishing: 33] [Article Influence: 7.2] [Reference Citation Analysis]
89 Zhang W, Huang R, Wang Y, Rao H, Wei L, Su GL, Lok AS. Fat Accumulation, Liver Fibrosis, and Metabolic Abnormalities in Chinese Patients With Moderate/Severe Versus Mild Hepatic Steatosis. Hepatol Commun 2019;3:1585-97. [PMID: 31832569 DOI: 10.1002/hep4.1435] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
90 Petta S, Di Marco V, Cammà C, Butera G, Cabibi D, Craxì A. Reliability of liver stiffness measurement in non-alcoholic fatty liver disease: the effects of body mass index. Aliment Pharmacol Ther. 2011;33:1350-1360. [PMID: 21517924 DOI: 10.1111/j.1365-2036.2011.04668.x] [Cited by in Crossref: 97] [Cited by in F6Publishing: 83] [Article Influence: 9.7] [Reference Citation Analysis]
91 Tziomalos K. Lipid-lowering agents in the management of nonalcoholic fatty liver disease. World J Hepatol 2014;6:738-44. [PMID: 25349644 DOI: 10.4254/wjh.v6.i10.738] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
92 Canbay A, Kachru N, Haas JS, Meise D, Ozbay AB, Sowa JP. Healthcare resource utilization and costs among nonalcoholic fatty liver disease patients in Germany. Ann Transl Med 2021;9:615. [PMID: 33987313 DOI: 10.21037/atm-20-7179] [Reference Citation Analysis]
93 Shen FF, Lu LG. Advances in noninvasive methods for diagnosing nonalcoholic fatty liver disease: Noninvasive methods to diagnose NAFLD. Journal of Digestive Diseases 2016;17:565-71. [DOI: 10.1111/1751-2980.12384] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
94 Kechagias S, Nasr P, Blomdahl J, Ekstedt M. Established and emerging factors affecting the progression of nonalcoholic fatty liver disease. Metabolism 2020;111S:154183. [PMID: 32061907 DOI: 10.1016/j.metabol.2020.154183] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 14.0] [Reference Citation Analysis]
95 Sartini A, Gitto S, Bianchini M, Verga MC, Di Girolamo M, Bertani A, Del Buono M, Schepis F, Lei B, De Maria N, Villa E. Non-alcoholic fatty liver disease phenotypes in patients with inflammatory bowel disease. Cell Death Dis. 2018;9:87. [PMID: 29367619 DOI: 10.1038/s41419-017-0124-2] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 9.7] [Reference Citation Analysis]
96 Cao W, Zhao C, Shen C, Wang Y. Cytokeratin 18, alanine aminotransferase, platelets and triglycerides predict the presence of nonalcoholic steatohepatitis. PLoS One 2013;8:e82092. [PMID: 24324749 DOI: 10.1371/journal.pone.0082092] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 3.1] [Reference Citation Analysis]
97 McPherson S, Wilkinson N, Tiniakos D, Wilkinson J, Burt AD, McColl E, Stocken DD, Steen N, Barnes J, Goudie N, Stewart S, Bury Y, Mann D, Anstee QM, Day CP. A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis. PLoS One 2017;12:e0175717. [PMID: 28419124 DOI: 10.1371/journal.pone.0175717] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 6.8] [Reference Citation Analysis]
98 Hu X, Geng H, Wang L, Xu H, Su Y, Liang S, Qian L. Supersonic Shear Wave Imaging of the Spleen for Staging of Liver Fibrosis in Rats. Ultrasound in Medicine & Biology 2017;43:2343-51. [DOI: 10.1016/j.ultrasmedbio.2017.04.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
99 Wong VW, Wong GL, Yeung DK, Lau TK, Chan CK, Chim AM, Abrigo JM, Chan RS, Woo J, Tse YK, Chu WC, Chan HL. Incidence of non-alcoholic fatty liver disease in Hong Kong: a population study with paired proton-magnetic resonance spectroscopy. J Hepatol. 2015;62:182-189. [PMID: 25195550 DOI: 10.1016/j.jhep.2014.08.041] [Cited by in Crossref: 94] [Cited by in F6Publishing: 83] [Article Influence: 13.4] [Reference Citation Analysis]
100 Yuan JM, Grouls M, Carmella SG, Wang R, Heskin A, Jiang Y, Tan YT, Adams-Haduch J, Gao YT, Hecht SS. Prediagnostic levels of urinary 8-epi-prostaglandin F2α and prostaglandin E2 metabolite, biomarkers of oxidative damage and inflammation, and risk of hepatocellular carcinoma. Carcinogenesis 2019;40:989-97. [PMID: 30615102 DOI: 10.1093/carcin/bgy180] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
101 Mohammed ED, Abdel-Naim AB, Kangpeng J, Jiang R, Wei J, Sun B. The mother relationship between insulin resistance and non-alcoholic steatohepatitis: Glucosinolates hydrolysis products as a promising insulin resistance-modulator and fatty liver-preventer. Life Sci 2021;264:118615. [PMID: 33096115 DOI: 10.1016/j.lfs.2020.118615] [Reference Citation Analysis]
102 Wong GL. Update of liver fibrosis and steatosis with transient elastography (Fibroscan). Gastroenterol Rep (Oxf) 2013;1:19-26. [PMID: 24759663 DOI: 10.1093/gastro/got007] [Cited by in Crossref: 57] [Cited by in F6Publishing: 54] [Article Influence: 7.1] [Reference Citation Analysis]
103 Kjærgaard K, Mikkelsen ACD, Wernberg CW, Grønkjær LL, Eriksen PL, Damholdt MF, Mookerjee RP, Vilstrup H, Lauridsen MM, Thomsen KL. Cognitive Dysfunction in Non-Alcoholic Fatty Liver Disease-Current Knowledge, Mechanisms and Perspectives. J Clin Med 2021;10:673. [PMID: 33572481 DOI: 10.3390/jcm10040673] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
104 Cheng J, Palva AM, de Vos WM, Satokari R. Contribution of the intestinal microbiota to human health: from birth to 100 years of age. Curr Top Microbiol Immunol. 2013;358:323-346. [PMID: 22094893 DOI: 10.1007/82_2011_189] [Cited by in Crossref: 14] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
105 Boutari C, Perakakis N, Mantzoros CS. Association of Adipokines with Development and Progression of Nonalcoholic Fatty Liver Disease. Endocrinol Metab (Seoul). 2018;33:33-43. [PMID: 29589386 DOI: 10.3803/enm.2018.33.1.33] [Cited by in Crossref: 61] [Cited by in F6Publishing: 35] [Article Influence: 20.3] [Reference Citation Analysis]
106 Cheng BC, Yen YH, Chen JF, Wu CK, Chang KC, Tseng PL, Tsai MC, Lin MT, Lin JT, Chen JB, Hu TH. Transient elastography as a screening tool for liver fibrosis in a large hemodialysis population. Sci Rep 2017;7:46458. [PMID: 28422172 DOI: 10.1038/srep46458] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
107 Yu J, Shen J, Sun TT, Zhang X, Wong N. Obesity, insulin resistance, NASH and hepatocellular carcinoma. Semin Cancer Biol. 2013;23:483-491. [PMID: 23876851 DOI: 10.1016/j.semcancer.2013.07.003] [Cited by in Crossref: 71] [Cited by in F6Publishing: 69] [Article Influence: 8.9] [Reference Citation Analysis]
108 Pastuszak M, Groszewski K, Pastuszak M, Dyrla P, Wojtuń S, Gil J. Cytokeratins in gastroenterology. Systematic review. Prz Gastroenterol 2015;10:61-70. [PMID: 26557935 DOI: 10.5114/pg.2015.51182] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
109 Chan WK, Treeprasertsuk S, Imajo K, Nakajima A, Seki Y, Kasama K, Kakizaki S, Fan JG, Song MJ, Yoon SK, Dan YY, Lesmana L, Ho KY, Goh KL, Wong VW. Clinical features and treatment of nonalcoholic fatty liver disease across the Asia Pacific region-the GO ASIA initiative. Aliment Pharmacol Ther. 2018;47:816-825. [PMID: 29333610 DOI: 10.1111/apt.14506] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 9.3] [Reference Citation Analysis]
110 Lonardo A, Ballestri S, Guaraldi G, Nascimbeni F, Romagnoli D, Zona S, Targher G. Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV. World J Gastroenterol. 2016;22:9674-9693. [PMID: 27956792 DOI: 10.3748/wjg.v22.i44.9674] [Cited by in CrossRef: 65] [Cited by in F6Publishing: 57] [Article Influence: 16.3] [Reference Citation Analysis]
111 Gerhard GS, Legendre C, Still CD, Chu X, Petrick A, DiStefano JK. Transcriptomic Profiling of Obesity-Related Nonalcoholic Steatohepatitis Reveals a Core Set of Fibrosis-Specific Genes. J Endocr Soc 2018;2:710-26. [PMID: 29978150 DOI: 10.1210/js.2018-00122] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 8.3] [Reference Citation Analysis]
112 Tiessen RG, Kennedy CA, Keller BT, Levin N, Acevedo L, Gedulin B, van Vliet AA, Dorenbaum A, Palmer M. Safety, tolerability and pharmacodynamics of apical sodium-dependent bile acid transporter inhibition with volixibat in healthy adults and patients with type 2 diabetes mellitus: a randomised placebo-controlled trial. BMC Gastroenterol 2018;18:3. [PMID: 29304731 DOI: 10.1186/s12876-017-0736-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
113 Kwak M, Kim D. Long-Term Outcomes of Nonalcoholic Fatty Liver Disease. Curr Hepatology Rep 2015;14:69-76. [DOI: 10.1007/s11901-015-0258-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
114 Shen J, Chan HL, Wong GL, Chan AW, Choi PC, Chan HY, Chim AM, Yeung DK, Yu J, Chu WC. Assessment of non-alcoholic fatty liver disease using serum total cell death and apoptosis markers. Aliment Pharmacol Ther. 2012;36:1057-1066. [PMID: 23066946 DOI: 10.1111/apt.12091] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 4.4] [Reference Citation Analysis]
115 Ishitobi T, Hyogo H, Tokumo H, Arihiro K, Chayama K. Efficacy of probucol for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label pilot study. Hepatol Res. 2013;Apr 17; Epub ahead of print. [PMID: 23607264 DOI: 10.1111/hepr.12135] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
116 Yki-Järvinen H. Diagnosis of non-alcoholic fatty liver disease (NAFLD). Diabetologia. 2016;59:1104-1111. [PMID: 27091184 DOI: 10.1007/s00125-016-3944-1] [Cited by in Crossref: 48] [Cited by in F6Publishing: 39] [Article Influence: 9.6] [Reference Citation Analysis]
117 McPherson S, Anstee QM, Henderson E, Day CP, Burt AD. Are simple noninvasive scoring systems for fibrosis reliable in patients with NAFLD and normal ALT levels? Eur J Gastroenterol Hepatol. 2013;25:652-658. [PMID: 23325287 DOI: 10.1097/meg.0b013e32835d72cf] [Cited by in Crossref: 49] [Cited by in F6Publishing: 22] [Article Influence: 6.1] [Reference Citation Analysis]
118 Taitano AA, Markow M, Finan JE, Wheeler DE, Gonzalvo JP, Murr MM. Bariatric surgery improves histological features of nonalcoholic fatty liver disease and liver fibrosis. J Gastrointest Surg. 2015;19:429-436; discussion 436-437. [PMID: 25537957 DOI: 10.1007/s11605-014-2678-y] [Cited by in Crossref: 71] [Cited by in F6Publishing: 57] [Article Influence: 10.1] [Reference Citation Analysis]
119 Danford CJ, Sanchez JE, Corey KE. Managing the Burden of Non-NASH NAFLD. Curr Hepatol Rep 2017;16:326-34. [PMID: 29503789 DOI: 10.1007/s11901-017-0371-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
120 Hydes TJ, Summers N, Brown E, Alam U, Thomaides-Brears H, Wilding JPH, Cuthbertson DJ. Mechanisms, screening modalities and treatment options for individuals with non-alcoholic fatty liver disease and type 2 diabetes. Diabet Med 2020;37:1793-806. [PMID: 32619031 DOI: 10.1111/dme.14356] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
121 Wong VW, Chan HL. Should all patients with nonalcoholic fatty liver disease undergo oral glucose tolerance test?: Editorials. Journal of Gastroenterology and Hepatology 2011;26:419-20. [DOI: 10.1111/j.1440-1746.2010.06594.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
122 Wong VW, Wong GL, Yeung JC, Fung CY, Chan JK, Chang ZH, Kwan CT, Lam H, Limquiaco J, Chim AM, Yu C, Chan HL. Long-term clinical outcomes after fatty liver screening in patients undergoing coronary angiogram: A prospective cohort study: Hepatology. Hepatology 2016;63:754-63. [DOI: 10.1002/hep.28253] [Cited by in Crossref: 59] [Cited by in F6Publishing: 46] [Article Influence: 9.8] [Reference Citation Analysis]
123 Teufel A, Itzel T, Erhart W, Brosch M, Wang XY, Kim YO, von Schönfels W, Herrmann A, Brückner S, Stickel F, Dufour JF, Chavakis T, Hellerbrand C, Spang R, Maass T, Becker T, Schreiber S, Schafmayer C, Schuppan D, Hampe J. Comparison of Gene Expression Patterns Between Mouse Models of Nonalcoholic Fatty Liver Disease and Liver Tissues From Patients. Gastroenterology 2016;151:513-525.e0. [PMID: 27318147 DOI: 10.1053/j.gastro.2016.05.051] [Cited by in Crossref: 113] [Cited by in F6Publishing: 102] [Article Influence: 22.6] [Reference Citation Analysis]
124 Conlon BA, Beasley JM, Aebersold K, Jhangiani SS, Wylie-Rosett J. Nutritional management of insulin resistance in nonalcoholic fatty liver disease (NAFLD). Nutrients. 2013;5:4093-4114. [PMID: 24152749 DOI: 10.3390/nu5104093] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 5.1] [Reference Citation Analysis]
125 van der Meer AJ, Maan R, Veldt BJ, Feld JJ, Wedemeyer H, Dufour J, Lammert F, Duarte-rojo A, Manns MP, Zeuzem S, Hofmann WP, de Knegt RJ, Hansen BE, Janssen HL. Improvement of platelets after SVR among patients with chronic HCV infection and advanced hepatic fibrosis: Platelets improve following HCV eradication. Journal of Gastroenterology and Hepatology 2016;31:1168-76. [DOI: 10.1111/jgh.13252] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 5.6] [Reference Citation Analysis]
126 Nasr P, Ignatova S, Kechagias S, Ekstedt M. Natural history of nonalcoholic fatty liver disease: A prospective follow-up study with serial biopsies. Hepatol Commun. 2018;2:199-210. [PMID: 29404527 DOI: 10.1002/hep4.1134] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 12.0] [Reference Citation Analysis]
127 Kwok R, Tse YK, Wong GL, Ha Y, Lee AU, Ngu MC, Chan HL, Wong VW. Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease--the role of transient elastography and plasma cytokeratin-18 fragments. Aliment Pharmacol Ther. 2014;39:254-269. [PMID: 24308774 DOI: 10.1111/apt.12569] [Cited by in Crossref: 228] [Cited by in F6Publishing: 191] [Article Influence: 28.5] [Reference Citation Analysis]
128 Blais P, Husain N, Kramer JR, Kowalkowski M, El-Serag H, Kanwal F. Nonalcoholic fatty liver disease is underrecognized in the primary care setting. Am J Gastroenterol 2015;110:10-4. [PMID: 24890441 DOI: 10.1038/ajg.2014.134] [Cited by in Crossref: 69] [Cited by in F6Publishing: 55] [Article Influence: 9.9] [Reference Citation Analysis]
129 Parker HM, O’connor HT, Keating SE, Cohn JS, Garg ML, Caterson ID, George J, Johnson NA. Efficacy of the Omega-3 Index in predicting non-alcoholic fatty liver disease in overweight and obese adults: a pilot study. Br J Nutr 2015;114:780-7. [DOI: 10.1017/s0007114515002305] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
130 Baranova A, Tran TP, Birerdinc A, Younossi ZM. Systematic review: association of polycystic ovary syndrome with metabolic syndrome and non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2011;33:801-814. [PMID: 21251033 DOI: 10.1111/j.1365-2036.2011.04579.x] [Cited by in Crossref: 77] [Cited by in F6Publishing: 62] [Article Influence: 7.7] [Reference Citation Analysis]
131 Nakahara T, Hyogo H, Kimura Y, Ishitobi T, Arihiro K, Aikata H, Takahashi S, Chayama K. Efficacy of rosuvastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label, pilot study. Hepatol Res 2012;42:1065-72. [PMID: 22583925 DOI: 10.1111/j.1872-034X.2012.01034.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 13] [Article Influence: 2.9] [Reference Citation Analysis]
132 Lee HW, Wong GL, Kwok R, Choi KC, Chan CK, Shu SS, Leung JK, Chim AM, Luk AO, Ma RC, Chan HL, Chan JC, Kong AP, Wong VW. Serial transient elastography examinations to monitor patients with type 2 diabetes: A prospective cohort study. Hepatology. 2020;. [PMID: 31991487 DOI: 10.1002/hep.31142] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
133 Sundelin EIO, Gormsen LC, Heebøll S, Vendelbo MH, Jakobsen S, Munk OL, Feddersen S, Brøsen K, Hamilton-Dutoit SJ, Pedersen SB, Grønbaek H, Jessen N. Hepatic exposure of metformin in patients with non-alcoholic fatty liver disease. Br J Clin Pharmacol 2019;85:1761-70. [PMID: 30973968 DOI: 10.1111/bcp.13962] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
134 Mazzolini G, Sowa JP, Atorrasagasti C, Kücükoglu Ö, Syn WK, Canbay A. Significance of Simple Steatosis: An Update on the Clinical and Molecular Evidence. Cells 2020;9:E2458. [PMID: 33187255 DOI: 10.3390/cells9112458] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
135 Pang J, Xu W, Zhang X, Wong GL, Chan AW, Chan H, Tse C, Shu SS, Choi PC, Chan HL, Yu J, Wong VW. Significant positive association of endotoxemia with histological severity in 237 patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2017;46:175-82. [DOI: 10.1111/apt.14119] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 8.8] [Reference Citation Analysis]
136 Rahimi RS, Landaverde C. Nonalcoholic fatty liver disease and the metabolic syndrome: clinical implications and treatment. Nutr Clin Pract. 2013;28:40-51. [PMID: 23286927 DOI: 10.1177/0884533612470464] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 5.0] [Reference Citation Analysis]
137 Hassan K, Bhalla V, El Regal ME, A-Kader HH. Nonalcoholic fatty liver disease: a comprehensive review of a growing epidemic. World J Gastroenterol. 2014;20:12082-12101. [PMID: 25232245 DOI: 10.3748/wjg.v20.i34.12082] [Cited by in CrossRef: 104] [Cited by in F6Publishing: 82] [Article Influence: 17.3] [Reference Citation Analysis]
138 Dall M, Penke M, Sulek K, Matz-Soja M, Holst B, Garten A, Kiess W, Treebak JT. Hepatic NAD+ levels and NAMPT abundance are unaffected during prolonged high-fat diet consumption in C57BL/6JBomTac mice. Mol Cell Endocrinol 2018;473:245-56. [PMID: 29408602 DOI: 10.1016/j.mce.2018.01.025] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
139 Hyogo H, Ikegami T, Tokushige K, Hashimoto E, Inui K, Matsuzaki Y, Tokumo H, Hino F, Tazuma S. Efficacy of pitavastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label, pilot study. Hepatol Res. 2011;41:1057-1065. [PMID: 21951922 DOI: 10.1111/j.1872-034x.2011.00849.x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
140 Mishra A, Younossi ZM. Epidemiology and Natural History of Non-alcoholic Fatty Liver Disease. J Clin Exp Hepatol. 2012;2:135-144. [PMID: 25755422 DOI: 10.1016/s0973-6883(12)60102-9] [Cited by in Crossref: 51] [Cited by in F6Publishing: 26] [Article Influence: 5.7] [Reference Citation Analysis]
141 Masterjohn C, Bruno RS. Therapeutic potential of green tea in nonalcoholic fatty liver disease. Nutr Rev. 2012;70:41-56. [PMID: 22221215 DOI: 10.1111/j.1753-4887.2011.00440.x] [Cited by in Crossref: 80] [Cited by in F6Publishing: 71] [Article Influence: 8.9] [Reference Citation Analysis]
142 Seto WK, Yuen MF. Nonalcoholic fatty liver disease in Asia: emerging perspectives. J Gastroenterol. 2017;52:164-174. [PMID: 27637587 DOI: 10.1007/s00535-016-1264-3] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 9.2] [Reference Citation Analysis]
143 Kontana A, Tziomalos K. Role of sodium-glucose co-transporter-2 inhibitors in the management of nonalcoholic fatty liver disease. World J Gastroenterol 2019;25:3664-8. [PMID: 31391764 DOI: 10.3748/wjg.v25.i28.3664] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
144 Zhou F, Zhou J, Wang W, Zhang XJ, Ji YX, Zhang P, She ZG, Zhu L, Cai J, Li H. Unexpected Rapid Increase in the Burden of NAFLD in China From 2008 to 2018: A Systematic Review and Meta-Analysis. Hepatology. 2019;70:1119-1133. [PMID: 31070259 DOI: 10.1002/hep.30702] [Cited by in Crossref: 88] [Cited by in F6Publishing: 83] [Article Influence: 88.0] [Reference Citation Analysis]
145 Ostovaneh MR, Zamani F, Ansari-moghaddam A, Sharafkhah M, Saeedian FS, Rohani Z, Khoonsari M, Barzin G, Hemmasi G, Ajdarkosh H, Katoonizadeh A, Maadi M, Malekzadeh R, Poustchi H. Nonalcoholic Fatty Liver: The Association with Metabolic Abnormalities, Body Mass Index and Central Obesity—A Population-Based Study. Metabolic Syndrome and Related Disorders 2015;13:304-11. [DOI: 10.1089/met.2014.0131] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
146 Su C, Chau G, Hung H, Yeh Y, Lei H, Hsia C, Lai C, Lin H, Wu J. Impact of Steatosis on Prognosis of Patients with Early-Stage Hepatocellular Carcinoma After Hepatic Resection. Ann Surg Oncol 2015;22:2253-61. [DOI: 10.1245/s10434-014-4221-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
147 Palmer M, Jennings L, Silberg DG, Bliss C, Martin P. A randomised, double-blind, placebo-controlled phase 1 study of the safety, tolerability and pharmacodynamics of volixibat in overweight and obese but otherwise healthy adults: implications for treatment of non-alcoholic steatohepatitis. BMC Pharmacol Toxicol 2018;19:10. [PMID: 29548345 DOI: 10.1186/s40360-018-0200-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
148 Shafiq M, Walmann T, Nutalapati V, Gibson C, Zafar Y. Effects of proprotein convertase subtilisin/kexin type-9 inhibitors on fatty liver. World J Hepatol 2020;12:1258-66. [PMID: 33442452 DOI: 10.4254/wjh.v12.i12.1258] [Reference Citation Analysis]
149 Wong GL, Wong VW. Non-alcoholic fatty liver disease in Asia: How is it different from the West? J Gastroenterol Hepatol 2019;34:1267-8. [PMID: 31456234 DOI: 10.1111/jgh.14813] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
150 Wong VW, Vergniol J, Wong GL, Foucher J, Chan AW, Chermak F, Choi PC, Merrouche W, Chu SH, Pesque S, Chan HL, de Lédinghen V. Liver Stiffness Measurement Using XL Probe in Patients With Nonalcoholic Fatty Liver Disease. American Journal of Gastroenterology 2012;107:1862-71. [DOI: 10.1038/ajg.2012.331] [Cited by in Crossref: 231] [Cited by in F6Publishing: 194] [Article Influence: 25.7] [Reference Citation Analysis]
151 Lee SS, Park SH. Radiologic evaluation of nonalcoholic fatty liver disease. World J Gastroenterol 2014;20:7392-402. [PMID: 24966609 DOI: 10.3748/wjg.v20.i23.7392] [Cited by in CrossRef: 197] [Cited by in F6Publishing: 158] [Article Influence: 32.8] [Reference Citation Analysis]
152 Mikolasevic I, Orlic L, Franjic N, Hauser G, Stimac D, Milic S. Transient elastography (FibroScan(®)) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand? World J Gastroenterol 2016;22:7236-51. [PMID: 27621571 DOI: 10.3748/wjg.v22.i32.7236] [Cited by in CrossRef: 100] [Cited by in F6Publishing: 90] [Article Influence: 25.0] [Reference Citation Analysis]
153 Machado MV, Cortez-Pinto H. Management of fatty liver disease with the metabolic syndrome. Expert Rev Gastroenterol Hepatol. 2014;8:487-500. [PMID: 24665862 DOI: 10.1586/17474124.2014.903798] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
154 Sanai FM, Abaalkhail F, Hasan F, Farooqi MH, Nahdi NA, Younossi ZM. Management of nonalcoholic fatty liver disease in the Middle East. World J Gastroenterol 2020;26:3528-41. [PMID: 32742124 DOI: 10.3748/wjg.v26.i25.3528] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
155 Arora A, Sharma P. Non-invasive Diagnosis of Fibrosis in Non-alcoholic Fatty Liver Disease. J Clin Exp Hepatol. 2012;2:145-155. [PMID: 25755423 DOI: 10.1016/s0973-6883(12)60103-0] [Cited by in Crossref: 25] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
156 Liu XL, Cao HX, Wang BC, Xin FZ, Zhang RN, Zhou D, Yang RX, Zhao ZH, Pan Q, Fan JG. miR-192-5p regulates lipid synthesis in non-alcoholic fatty liver disease through SCD-1. World J Gastroenterol 2017;23:8140-51. [PMID: 29290651 DOI: 10.3748/wjg.v23.i46.8140] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 27] [Article Influence: 9.3] [Reference Citation Analysis]
157 Besse-Patin A, Estall JL. An Intimate Relationship between ROS and Insulin Signalling: Implications for Antioxidant Treatment of Fatty Liver Disease. Int J Cell Biol 2014;2014:519153. [PMID: 24672550 DOI: 10.1155/2014/519153] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.9] [Reference Citation Analysis]
158 Oda K, Uto H, Mawatari S, Ido A. Clinical features of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: a review of human studies. Clin J Gastroenterol. 2015;8:1-9. [PMID: 25575848 DOI: 10.1007/s12328-014-0548-5] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 6.8] [Reference Citation Analysis]
159 Baffy G. Hepatocellular Carcinoma in Obesity: Finding a Needle in the Haystack? In: Yu J, editor. Obesity, Fatty Liver and Liver Cancer. Singapore: Springer; 2018. pp. 63-77. [DOI: 10.1007/978-981-10-8684-7_6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
160 Anty R, Lemoine M. Liver fibrogenesis and metabolic factors. Clin Res Hepatol Gastroenterol. 2011;35 Suppl 1:S10-S20. [PMID: 21742296 DOI: 10.1016/s2210-7401(11)70003-1] [Cited by in Crossref: 26] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
161 Italian Association for the Study of the Liver (AISF). AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions. Dig Liver Dis. 2017;49:471-483. [PMID: 28215516 DOI: 10.1016/j.dld.2017.01.147] [Cited by in Crossref: 161] [Cited by in F6Publishing: 144] [Article Influence: 40.3] [Reference Citation Analysis]
162 Kosmalski M, Mokros Ł, Kuna P, Witusik A, Pietras T. Changes in the immune system - the key to diagnostics and therapy of patients with non-alcoholic fatty liver disease. Cent Eur J Immunol 2018;43:231-9. [PMID: 30135638 DOI: 10.5114/ceji.2018.77395] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
163 Salic K, Kleemann R, Wilkins-Port C, McNulty J, Verschuren L, Palmer M. Apical sodium-dependent bile acid transporter inhibition with volixibat improves metabolic aspects and components of non-alcoholic steatohepatitis in Ldlr-/-.Leiden mice. PLoS One 2019;14:e0218459. [PMID: 31233523 DOI: 10.1371/journal.pone.0218459] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 8.0] [Reference Citation Analysis]
164 Loomba R, Jain A, Diehl AM, Guy CD, Portenier D, Sudan R, Singh S, Faulkner C, Richards L, Hester KD, Okada L, Li XJ, Mimms L, Abdelmalek MF. Validation of Serum Test for Advanced Liver Fibrosis in Patients With Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol 2019;17:1867-1876.e3. [PMID: 30448594 DOI: 10.1016/j.cgh.2018.11.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
165 Toman D, Vavra P, Jelinek P, Ostruszka P, Ihnat P, Foltys A, Pelikan A, Roman J. Effect of bariatric surgery on fatty liver disease in obese patients: A prospective one year follow-up study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2021. [PMID: 33885048 DOI: 10.5507/bp.2021.021] [Reference Citation Analysis]
166 Abrigo JM, Shen J, Wong VW, Yeung DK, Wong GL, Chim AM, Chan AW, Choi PC, Chan FK, Chan HL, Chu WC. Non-alcoholic fatty liver disease: spectral patterns observed from an in vivo phosphorus magnetic resonance spectroscopy study. J Hepatol 2014;60:809-15. [PMID: 24291241 DOI: 10.1016/j.jhep.2013.11.018] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
167 Leti F, Legendre C, Still CD, Chu X, Petrick A, Gerhard GS, DiStefano JK. Altered expression of MALAT1 lncRNA in nonalcoholic steatohepatitis fibrosis regulates CXCL5 in hepatic stellate cells. Transl Res 2017;190:25-39.e21. [PMID: 28993096 DOI: 10.1016/j.trsl.2017.09.001] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 11.0] [Reference Citation Analysis]
168 McCarty TR, Echouffo-Tcheugui JB, Lange A, Haque L, Njei B. Impact of bariatric surgery on outcomes of patients with nonalcoholic fatty liver disease: a nationwide inpatient sample analysis, 2004-2012. Surg Obes Relat Dis. 2018;14:74-80. [PMID: 29055669 DOI: 10.1016/j.soard.2017.09.511] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
169 Bendtsen F, Dam-larsen S. Long-Term, Clinical Follow-Up in Fatty Liver Patients. Dig Dis 2010;28:709-14. [DOI: 10.1159/000324277] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
170 Jonscher KR, Bruce KD. Current Models of Fatty Liver Disease; New Insights, Therapeutic Targets and Interventions. Adv Exp Med Biol 2019;1134:33-58. [PMID: 30919331 DOI: 10.1007/978-3-030-12668-1_3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
171 Alukal JJ, Thuluvath PJ. Reversal of NASH fibrosis with pharmacotherapy. Hepatol Int 2019;13:534-45. [PMID: 31363910 DOI: 10.1007/s12072-019-09970-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
172 Abbas Z, Shazi L. Pattern and profile of chronic liver disease in acute on chronic liver failure. Hepatol Int 2015;9:366-72. [PMID: 26016461 DOI: 10.1007/s12072-015-9627-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
173 Jayaraman T, Lee YY, Chan WK, Mahadeva S. Epidemiological differences of common liver conditions between Asia and the West. JGH Open. 2020;4:332-339. [PMID: 32514433 DOI: 10.1002/jgh3.12275] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
174 Wong VW. Nonalcoholic fatty liver disease in Asia: a story of growth. J Gastroenterol Hepatol. 2013;28:18-23. [PMID: 23094755 DOI: 10.1111/jgh.12011] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 6.1] [Reference Citation Analysis]
175 Shimizu M, Suzuki K, Kato K, Jojima T, Iijima T, Murohisa T, Iijima M, Takekawa H, Usui I, Hiraishi H, Aso Y. Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease. Diabetes Obes Metab 2019;21:285-92. [DOI: 10.1111/dom.13520] [Cited by in Crossref: 106] [Cited by in F6Publishing: 89] [Article Influence: 35.3] [Reference Citation Analysis]
176 Purcaru MAP, Repanovici A, Nedeloiu T. Non-Invasive Assessment Method Using Thoracic-Abdominal Profile Image Acquisition and Mathematical Modeling with Bezier Curves. J Clin Med 2019;8:E65. [PMID: 30634482 DOI: 10.3390/jcm8010065] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
177 McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol. 2015;62:1148-1155. [PMID: 25477264 DOI: 10.1016/j.jhep.2014.11.034] [Cited by in Crossref: 526] [Cited by in F6Publishing: 445] [Article Influence: 75.1] [Reference Citation Analysis]
178 Wong GL, Wong VW. Fat and Fiber: How the Controlled Attenuation Parameter Complements Noninvasive Assessment of Liver Fibrosis. Dig Dis Sci 2015;60:9-12. [DOI: 10.1007/s10620-014-3429-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
179 Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34:274-285. [PMID: 21623852 DOI: 10.1111/j.1365-2036.2011.04724.x] [Cited by in Crossref: 1806] [Cited by in F6Publishing: 1587] [Article Influence: 180.6] [Reference Citation Analysis]
180 Mencin AA, Loomba R, Lavine JE. Caring for children with NAFLD and navigating their care into adulthood. Nat Rev Gastroenterol Hepatol 2015;12:617-28. [PMID: 26323878 DOI: 10.1038/nrgastro.2015.146] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
181 Tian Y, Wong VW, Chan HL, Cheng AS. Epigenetic regulation of hepatocellular carcinoma in non-alcoholic fatty liver disease. Semin Cancer Biol. 2013;23:471-482. [PMID: 24018165 DOI: 10.1016/j.semcancer.2013.08.010] [Cited by in Crossref: 51] [Cited by in F6Publishing: 42] [Article Influence: 6.4] [Reference Citation Analysis]
182 Joka D, Wahl K, Moeller S, Schlue J, Vaske B, Bahr MJ, Manns MP, Schulze-osthoff K, Bantel H. Prospective biopsy-controlled evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic steatohepatitis. Hepatology 2012;55:455-64. [DOI: 10.1002/hep.24734] [Cited by in Crossref: 125] [Cited by in F6Publishing: 109] [Article Influence: 12.5] [Reference Citation Analysis]
183 Zou A, Magee N, Deng F, Lehn S, Zhong C, Zhang Y. Hepatocyte nuclear receptor SHP suppresses inflammation and fibrosis in a mouse model of nonalcoholic steatohepatitis. J Biol Chem 2018;293:8656-71. [PMID: 29666185 DOI: 10.1074/jbc.RA117.001653] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 5.3] [Reference Citation Analysis]
184 Sohrabpour AA, Mohamadnejad M, Malekzadeh R. Review article: the reversibility of cirrhosis. Aliment Pharmacol Ther 2012;36:824-32. [PMID: 22966946 DOI: 10.1111/apt.12044] [Cited by in Crossref: 39] [Cited by in F6Publishing: 27] [Article Influence: 4.9] [Reference Citation Analysis]
185 Lomonaco R, Sunny NE, Bril F, Cusi K. Nonalcoholic fatty liver disease: current issues and novel treatment approaches. Drugs. 2013;73:1-14. [PMID: 23329465 DOI: 10.1007/s40265-012-0004-0] [Cited by in Crossref: 105] [Cited by in F6Publishing: 91] [Article Influence: 13.1] [Reference Citation Analysis]
186 Chan WK, Ida NH, Cheah PL, Goh KL. Progression of liver disease in non-alcoholic fatty liver disease: a prospective clinicopathological follow-up study. J Dig Dis. 2014;15:545-552. [PMID: 25060399 DOI: 10.1111/1751-2980.12175] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
187 Mora SI, García-román J, Gómez-ñañez I, García-román R. Chronic liver diseases and the potential use of S-adenosyl-l-methionine as a hepatoprotector. European Journal of Gastroenterology & Hepatology 2018;30:893-900. [DOI: 10.1097/meg.0000000000001141] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]
188 Ozturk Y, Soylu OB. Fatty liver in childhood. World J Hepatol 2014;6:33-40. [PMID: 24653792 DOI: 10.4254/wjh.v6.i1.33] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
189 Ekstedt M, Hagström H, Nasr P, Fredrikson M, Stål P, Kechagias S, Hultcrantz R. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015;61:1547-54. [DOI: 10.1002/hep.27368] [Cited by in Crossref: 1010] [Cited by in F6Publishing: 865] [Article Influence: 168.3] [Reference Citation Analysis]
190 Bower G, Toma T, Harling L, Jiao LR, Efthimiou E, Darzi A, Athanasiou T, Ashrafian H. Bariatric Surgery and Non-Alcoholic Fatty Liver Disease: a Systematic Review of Liver Biochemistry and Histology. Obes Surg. 2015;25:2280-2289. [PMID: 25917981 DOI: 10.1007/s11695-015-1691-x] [Cited by in Crossref: 131] [Cited by in F6Publishing: 97] [Article Influence: 26.2] [Reference Citation Analysis]
191 Wong S, Chan W. Epidemiology of non-alcoholic fatty liver disease in Asia. Indian J Gastroenterol 2020;39:1-8. [DOI: 10.1007/s12664-020-01018-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 11.0] [Reference Citation Analysis]
192 Uslusoy HS, Nak SG, Gülten M. Noninvasive predictors for liver fibrosis in patients with nonalcoholic steatohepatitis. World J Hepatol 2011;3:219-27. [PMID: 21954411 DOI: 10.4254/wjh.v3.i8.219] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
193 Dohmen J, Praktiknjo M, Rudeloff A, Uschner FE, Klein S, Plamper A, Matthaei H, Rheinwalt KP, Wehner S, Kalff JC, Trebicka J, Lingohr P. Impact of sleeve gastrectomy and dietary change on metabolic and hepatic function in an obesity rat model - Experimental research. Int J Surg 2020;75:139-47. [PMID: 32014594 DOI: 10.1016/j.ijsu.2020.01.139] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
194 Wong GL. Prediction of fibrosis progression in chronic viral hepatitis. Clin Mol Hepatol 2014;20:228-36. [PMID: 25320725 DOI: 10.3350/cmh.2014.20.3.228] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.1] [Reference Citation Analysis]
195 Huang P, Huang FZ, Liu HZ, Zhang TY, Yang MS, Sun CZ. LncRNA MEG3 functions as a ceRNA in regulating hepatic lipogenesis by competitively binding to miR-21 with LRP6. Metabolism 2019;94:1-8. [PMID: 30711569 DOI: 10.1016/j.metabol.2019.01.018] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 16.5] [Reference Citation Analysis]
196 Wei JL, Leung JC, Loong TC, Wong GL, Yeung DK, Chan RS, Chan HL, Chim AM, Woo J, Chu WC, Wong VW. Prevalence and Severity of Nonalcoholic Fatty Liver Disease in Non-Obese Patients: A Population Study Using Proton-Magnetic Resonance Spectroscopy. Am J Gastroenterol. 2015;110:1306-14; quiz 1315. [PMID: 26215532 DOI: 10.1038/ajg.2015.235] [Cited by in Crossref: 148] [Cited by in F6Publishing: 128] [Article Influence: 24.7] [Reference Citation Analysis]
197 Li M, Reynolds CM, Segovia SA, Gray C, Vickers MH. Developmental Programming of Nonalcoholic Fatty Liver Disease: The Effect of Early Life Nutrition on Susceptibility and Disease Severity in Later Life. Biomed Res Int 2015;2015:437107. [PMID: 26090409 DOI: 10.1155/2015/437107] [Cited by in Crossref: 10] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
198 Lindenmeyer CC, McCullough AJ. The Natural History of Nonalcoholic Fatty Liver Disease-An Evolving View. Clin Liver Dis. 2018;22:11-21. [PMID: 29128051 DOI: 10.1016/j.cld.2017.08.003] [Cited by in Crossref: 79] [Cited by in F6Publishing: 65] [Article Influence: 26.3] [Reference Citation Analysis]
199 Hazlehurst JM, Woods C, Marjot T, Cobbold JF, Tomlinson JW. Non-alcoholic fatty liver disease and diabetes. Metabolism 2016;65:1096-108. [PMID: 26856933 DOI: 10.1016/j.metabol.2016.01.001] [Cited by in Crossref: 205] [Cited by in F6Publishing: 171] [Article Influence: 41.0] [Reference Citation Analysis]
200 Kim GH, Chung JW, Lee JH, Ok KS, Jang ES, Kim J, Shin CM, Park YS, Hwang JH, Jeong SH, Kim N, Lee DH, Kim JW. Effect of vitamin E in nonalcoholic fatty liver disease with metabolic syndrome: A propensity score-matched cohort study. Clin Mol Hepatol 2015;21:379-86. [PMID: 26770927 DOI: 10.3350/cmh.2015.21.4.379] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
201 Wong VW, Wong GL, Chan AW, Chu WC, Choi PC, Chim AM, Yiu KK, Yu J, Chan FK, Chan HL. Treatment of non-alcoholic steatohepatitis with Phyllanthus urinaria : A randomized trial: Phyllanthus for NASH. J Gastroenterol Hepatol 2013;28:57-62. [DOI: 10.1111/j.1440-1746.2012.07286.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
202 Bellentani S. The epidemiology of non-alcoholic fatty liver disease. Liver Int. 2017;37 Suppl 1:81-84. [PMID: 28052624 DOI: 10.1111/liv.13299] [Cited by in Crossref: 312] [Cited by in F6Publishing: 245] [Article Influence: 78.0] [Reference Citation Analysis]
203 Calzadilla-Bertot L, Vilar-Gomez E, Wong VW, Romero-Gomez M, Aller-de la Fuente R, Wong GL, Castellanos M, Eslam M, Desai AP, Jeffrey GP, George J, Chalasani N, Adams LA. ABIDE: An Accurate Predictive Model of Liver Decompensation in Patients With Nonalcoholic Fatty Liver-Related Cirrhosis. Hepatology 2021;73:2238-50. [PMID: 32978796 DOI: 10.1002/hep.31576] [Reference Citation Analysis]
204 Yu XY, Li Y, Liu T, Wang RT. Association of whole blood viscosity with non-alcoholic fatty liver disease. Clin Hemorheol Microcirc 2015;62:335-43. [PMID: 26444605 DOI: 10.3233/CH-151974] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
205 Filozof C, Goldstein BJ, Williams RN, Sanyal A. Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval Pathway. Drugs 2015;75:1373-92. [PMID: 26201461 DOI: 10.1007/s40265-015-0437-3] [Cited by in Crossref: 47] [Cited by in F6Publishing: 38] [Article Influence: 9.4] [Reference Citation Analysis]
206 Negro F. Natural history of NASH and HCC. Liver Int 2020;40:72-6. [DOI: 10.1111/liv.14362] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 26.0] [Reference Citation Analysis]
207 Fielding CM, Angulo P. Hepatic steatosis and steatohepatitis: Are they really two distinct entities? Curr Hepatol Rep 2014;13:151-8. [PMID: 24977111 DOI: 10.1007/s11901-014-0227-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
208 Verhaegh P, Bavalia R, Winkens B, Masclee A, Jonkers D, Koek G. Noninvasive Tests Do Not Accurately Differentiate Nonalcoholic Steatohepatitis From Simple Steatosis: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology 2018;16:837-61. [DOI: 10.1016/j.cgh.2017.08.024] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 6.3] [Reference Citation Analysis]
209 Arrese M, Arab JP, Barrera F, Kaufmann B, Valenti L, Feldstein AE. Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity. Semin Liver Dis 2021. [PMID: 34233370 DOI: 10.1055/s-0041-1730927] [Reference Citation Analysis]
210 Daijo K, Nakahara T, Inagaki Y, Nanba M, Nishida Y, Uchikawa S, Kodama K, Oya K, Morio K, Fujino H, Ono A, Murakami E, Yamauchi M, Kawaoka T, Miki D, Tsuge M, Hiramatsu A, Hayes CN, Imamura M, Aikata H, Ochi H, Chayama K. Risk factors for histological progression of non-alcoholic steatohepatitis analyzed from repeated biopsy cases. J Gastroenterol Hepatol 2020;35:1412-9. [PMID: 31896166 DOI: 10.1111/jgh.14968] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
211 Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 2015; 13: 643-54. quiz e39-40. [PMID: 24768810 DOI: 10.1016/j.cgh.2014.04.014] [Cited by in Crossref: 683] [Cited by in F6Publishing: 586] [Article Influence: 97.6] [Reference Citation Analysis]
212 Bhala N, George J. The Burden of Non-alcoholic Fatty Liver Disease (NAFLD) in the Asia Pacific Region. Curr Hepatology Rep 2015;14:77-86. [DOI: 10.1007/s11901-015-0264-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
213 Moon HS, Dalamaga M, Kim SY, Polyzos SA, Hamnvik OP, Magkos F, Paruthi J, Mantzoros CS. Leptin's role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individuals. Endocr Rev. 2013;34:377-412. [PMID: 23475416 DOI: 10.1210/er.2012-1053] [Cited by in Crossref: 149] [Cited by in F6Publishing: 135] [Article Influence: 18.6] [Reference Citation Analysis]
214 Sagara M, Iijima T, Kase M, Kato K, Sakurai S, Tomaru T, Jojima T, Usui I, Aso Y. Serum levels of soluble dipeptidyl peptidase-4 in type 2 diabetes are associated with severity of liver fibrosis evaluated by transient elastography (FibroScan) and the FAST (FibroScan-AST) score, a novel index of non-alcoholic steatohepatitis with significant fibrosis. J Diabetes Complications 2021;35:107885. [PMID: 33602617 DOI: 10.1016/j.jdiacomp.2021.107885] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
215 Bellentani S, Marino M. Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD). Ann Hepatol. 2009;8 Suppl 1:S4-S8. [PMID: 19381118 DOI: 10.1002/cld.27] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
216 Salarian M, Turaga RC, Xue S, Nezafati M, Hekmatyar K, Qiao J, Zhang Y, Tan S, Ibhagui OY, Hai Y, Li J, Mukkavilli R, Sharma M, Mittal P, Min X, Keilholz S, Yu L, Qin G, Farris AB, Liu ZR, Yang JJ. Early detection and staging of chronic liver diseases with a protein MRI contrast agent. Nat Commun 2019;10:4777. [PMID: 31664017 DOI: 10.1038/s41467-019-11984-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 11.0] [Reference Citation Analysis]
217 Kerut SE, Balart JT, Kerut EK, McMullan MR. Diagnosis of fatty liver by computed tomography coronary artery calcium score. Echocardiography 2017;34:937-8. [PMID: 28493399 DOI: 10.1111/echo.13545] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
218 Wang Y, Yu Y, Wan H, Chen Y, Xia F, Zhang W, Zhang K, Gu X, Zhang Y, Lin Z, Yu Y, Wang N, Lu Y. Lower eGFR is associated with increased probability of liver fibrosis in Chinese diabetic patients. Diabetes Metab Res Rev 2020;36:e3294. [PMID: 32017389 DOI: 10.1002/dmrr.3294] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
219 Schuppan D, Schattenberg JM. Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches. J Gastroenterol Hepatol. 2013;28 Suppl 1:68-76. [PMID: 23855299 DOI: 10.1111/jgh.12212] [Cited by in Crossref: 148] [Cited by in F6Publishing: 134] [Article Influence: 21.1] [Reference Citation Analysis]
220 Wong VW, Wong GL, Chu WC, Chim AM, Ong A, Yeung DK, Yiu KK, Chu SH, Chan HY, Woo J, Chan FK, Chan HL. Hepatitis B virus infection and fatty liver in the general population. J Hepatol. 2012;56:533-540. [PMID: 22027575 DOI: 10.1016/j.jhep.2011.09.013] [Cited by in Crossref: 137] [Cited by in F6Publishing: 123] [Article Influence: 13.7] [Reference Citation Analysis]
221 Petäjä E, Yki-järvinen H. Definitions of Normal Liver Fat and the Association of Insulin Sensitivity with Acquired and Genetic NAFLD—A Systematic Review. IJMS 2016;17:633. [DOI: 10.3390/ijms17050633] [Cited by in Crossref: 75] [Cited by in F6Publishing: 59] [Article Influence: 15.0] [Reference Citation Analysis]
222 Gnocchi D, Custodero C, Sabbà C, Mazzocca A. Circadian rhythms: a possible new player in non-alcoholic fatty liver disease pathophysiology. J Mol Med (Berl) 2019;97:741-59. [PMID: 30953079 DOI: 10.1007/s00109-019-01780-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
223 Farrell GC, Wong VW, Chitturi S. NAFLD in Asia--as common and important as in the West. Nat Rev Gastroenterol Hepatol. 2013;10:307-318. [PMID: 23458891 DOI: 10.1038/nrgastro.2013. 34] [Reference Citation Analysis]
224 Wong GL, Chan HL. Two are better than one: noninvasive assessment of liver fibrosis in nonalcoholic fatty liver disease. Hepatol Int 2015;9:481-3. [DOI: 10.1007/s12072-015-9625-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
225 Leitão HS, Paulino C, Rodrigues D, Gonçalves SI, Marques C, Carvalheiro M, Geraldes CF, Caseiro-alves F. MR Fat Fraction Mapping. Academic Radiology 2013;20:957-61. [DOI: 10.1016/j.acra.2013.05.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
226 Williams KH, Shackel NA, Gorrell MD, McLennan SV, Twigg SM. Diabetes and nonalcoholic Fatty liver disease: a pathogenic duo. Endocr Rev. 2013;34:84-129. [PMID: 23238855 DOI: 10.1210/er.2012-1009] [Cited by in Crossref: 132] [Cited by in F6Publishing: 121] [Article Influence: 14.7] [Reference Citation Analysis]
227 Armstrong MJ, Houlihan DD, Newsome PN. NAFLD is underrecognized in the primary care setting: UK experience. Am J Gastroenterol 2014;109:1500-1. [PMID: 25196882 DOI: 10.1038/ajg.2014.207] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
228 Yang M, Xu D, Liu Y, Guo X, Li W, Guo C, Zhang H, Gao Y, Mao Y, Zhao J. Combined Serum Biomarkers in Non-Invasive Diagnosis of Non-Alcoholic Steatohepatitis. PLoS One. 2015;10:e0131664. [PMID: 26121037 DOI: 10.1371/journal.pone.0131664] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 5.7] [Reference Citation Analysis]
229 Blake L, Duarte RV, Cummins C. Decision analytic model of the diagnostic pathways for patients with suspected non-alcoholic fatty liver disease using non-invasive transient elastography and multiparametric magnetic resonance imaging. BMJ Open 2016;6:e010507. [PMID: 27650757 DOI: 10.1136/bmjopen-2015-010507] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
230 Sakamoto Y, Yoshio S, Doi H, Kawai H, Shimagaki T, Mori T, Matsuda M, Aoki Y, Osawa Y, Yoshida Y, Arai T, Itokawa N, Ito T, Seko Y, Yamaguchi K, Itoh Y, Mise Y, Saiura A, Taketomi A, Kanto T. Serum soluble sialic acid‐binding immunoglobulin‐like lectin‐7 concentration as an indicator of liver macrophage activation and advanced fibrosis in patients with non‐alcoholic fatty liver disease. Hepatol Res 2020;50:466-77. [DOI: 10.1111/hepr.13464] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
231 Zelber-Sagi S, Lotan R, Shlomai A, Webb M, Harrari G, Buch A, Nitzan Kaluski D, Halpern Z, Oren R. Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up. J Hepatol. 2012;56:1145-1151. [PMID: 22245895 DOI: 10.1016/j.jhep.2011.12.011] [Cited by in Crossref: 148] [Cited by in F6Publishing: 128] [Article Influence: 16.4] [Reference Citation Analysis]
232 Lang S, Martin A, Zhang X, Farowski F, Wisplinghoff H, J G T Vehreschild M, Krawczyk M, Nowag A, Kretzschmar A, Scholz C, Kasper P, Roderburg C, Mohr R, Lammert F, Tacke F, Schnabl B, Goeser T, Steffen HM, Demir M. Combined analysis of gut microbiota, diet and PNPLA3 polymorphism in biopsy-proven non-alcoholic fatty liver disease. Liver Int 2021;41:1576-91. [PMID: 33896117 DOI: 10.1111/liv.14899] [Reference Citation Analysis]
233 Yip TC, Wong VW, Chan HL, Tse YK, Hui VW, Liang LY, Lee HW, Lui GC, Kong AP, Wong GL. Thiazolidinediones reduce the risk of hepatocellular carcinoma and hepatic events in diabetic patients with chronic hepatitis B. J Viral Hepat 2020;27:904-14. [PMID: 32340077 DOI: 10.1111/jvh.13307] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
234 Martínez-Uña M, López-Mancheño Y, Diéguez C, Fernández-Rojo MA, Novelle MG. Unraveling the Role of Leptin in Liver Function and Its Relationship with Liver Diseases. Int J Mol Sci 2020;21:E9368. [PMID: 33316927 DOI: 10.3390/ijms21249368] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
235 Anty R, Iannelli A, Patouraux S, Bonnafous S, Lavallard VJ, Senni-Buratti M, Amor IB, Staccini-Myx A, Saint-Paul MC, Berthier F, Huet PM, Le Marchand-Brustel Y, Gugenheim J, Gual P, Tran A. A new composite model including metabolic syndrome, alanine aminotransferase and cytokeratin-18 for the diagnosis of non-alcoholic steatohepatitis in morbidly obese patients. Aliment Pharmacol Ther. 2010;32:1315-1322. [PMID: 21050233 DOI: 10.1111/j.1365-2036.2010.04480.x] [Cited by in Crossref: 92] [Cited by in F6Publishing: 77] [Article Influence: 8.4] [Reference Citation Analysis]
236 Hoodeshenas S, Yin M, Venkatesh SK. Magnetic Resonance Elastography of Liver: Current Update. Top Magn Reson Imaging. 2018;27:319-333. [PMID: 30289828 DOI: 10.1097/rmr.0000000000000177] [Cited by in Crossref: 39] [Cited by in F6Publishing: 9] [Article Influence: 19.5] [Reference Citation Analysis]
237 Lee KW, Devaraj NK, Ching SM, Veettil SK, Hoo FK, Deuraseh I, Soo MJ. Effect of SGLT-2 Inhibitors on Non-alcoholic Fatty Liver Disease among Patients with Type 2 Diabetes Mellitus: Systematic Review with Meta-analysis and Trial Sequential Analysis of Randomized Clinical Trials. Oman Med J 2021;36:e273. [PMID: 34239714 DOI: 10.5001/omj.2021.62] [Reference Citation Analysis]
238 Mikolasevic I, Milic S, Orlic L, Stimac D, Franjic N, Targher G. Factors associated with significant liver steatosis and fibrosis as assessed by transient elastography in patients with one or more components of the metabolic syndrome. Journal of Diabetes and its Complications 2016;30:1347-53. [DOI: 10.1016/j.jdiacomp.2016.05.014] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
239 Yoo JJ, Seo YS, Kim YS, Jeong SW, Jang JY, Suh SJ, Yim HJ, Suk KT, Kim DJ, Han KH, Kim SU, Lee B, Kim SG. The Influence of Histologic Inflammation on the Improvement of Liver Stiffness Values Over 1 and 3 Years. J Clin Med 2019;8:E2065. [PMID: 31771253 DOI: 10.3390/jcm8122065] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
240 Lemoine M, Serfaty L, Capeau J. From nonalcoholic fatty liver to nonalcoholic steatohepatitis and cirrhosis in HIV-infected patients: diagnosis and management. Current Opinion in Infectious Diseases 2012;25:10-6. [DOI: 10.1097/qco.0b013e32834ef599] [Cited by in Crossref: 49] [Cited by in F6Publishing: 24] [Article Influence: 5.4] [Reference Citation Analysis]
241 Kumar R, Priyadarshi RN, Anand U. Non-alcoholic Fatty Liver Disease: Growing Burden, Adverse Outcomes and Associations. J Clin Transl Hepatol 2020;8:76-86. [PMID: 32274348 DOI: 10.14218/JCTH.2019.00051] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
242 Adolph TE, Grander C, Grabherr F, Tilg H. Adipokines and Non-Alcoholic Fatty Liver Disease: Multiple Interactions. Int J Mol Sci 2017;18:E1649. [PMID: 28758929 DOI: 10.3390/ijms18081649] [Cited by in Crossref: 71] [Cited by in F6Publishing: 65] [Article Influence: 17.8] [Reference Citation Analysis]
243 Xiong Q, Wu Y, Yang M, Wu G, Wang Y, Wang H, Feng J, Song L, Tong B, He G, Xu Y. Nr2e1 ablation impairs liver glucolipid metabolism and induces inflammation, high-fat diets amplify the damage. Biomedicine & Pharmacotherapy 2019;120:109503. [DOI: 10.1016/j.biopha.2019.109503] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
244 Liu K, Mccaughan GW. Epidemiology and Etiologic Associations of Non-alcoholic Fatty Liver Disease and Associated HCC. In: Yu J, editor. Obesity, Fatty Liver and Liver Cancer. Singapore: Springer; 2018. pp. 3-18. [DOI: 10.1007/978-981-10-8684-7_2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
245 Tampi RP, Wong VW, Wong GL, Shu SS, Chan HL, Fung J, Stepanova M, Younossi ZM. Modelling the economic and clinical burden of non‐alcoholic steatohepatitis in East Asia: Data from Hong Kong. Hepatol Res 2020;50:1024-31. [DOI: 10.1111/hepr.13535] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
246 Seko Y, Sumida Y, Tanaka S, Mori K, Taketani H, Ishiba H, Hara T, Okajima A, Yamaguchi K, Moriguchi M, Mitsuyoshi H, Kanemasa K, Yasui K, Minami M, Imai S, Itoh Y. Serum alanine aminotransferase predicts the histological course of non-alcoholic steatohepatitis in Japanese patients: ALT in NASH progression. Hepatol Res 2015;45:E53-61. [DOI: 10.1111/hepr.12456] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 3.7] [Reference Citation Analysis]
247 Banini BA, Sanyal AJ. Nonalcoholic Fatty Liver Disease: Epidemiology, Pathogenesis, Natural History, Diagnosis, and Current Treatment Options. Clin Med Insights Ther 2016;8:75-84. [PMID: 28670148 DOI: 10.4137/cmt.s18885] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
248 Polyzos SA, Kountouras J, Mantzoros CS. Adipokines in nonalcoholic fatty liver disease. Metabolism 2016;65:1062-79. [DOI: 10.1016/j.metabol.2015.11.006] [Cited by in Crossref: 147] [Cited by in F6Publishing: 133] [Article Influence: 29.4] [Reference Citation Analysis]
249 Tan HL, Mohamed R, Mohamed Z, Zain SM. Phosphatidylethanolamine N-methyltransferase gene rs7946 polymorphism plays a role in risk of nonalcoholic fatty liver disease: evidence from meta-analysis. Pharmacogenet Genomics. 2016;26:88-95. [PMID: 26636496 DOI: 10.1097/fpc.0000000000000193] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
250 Suzuki K, Yoneda M, Imajo K, Kirikoshi H, Nakajima A, Maeda S, Saito S. Transient elastography for monitoring the fibrosis of non-alcoholic fatty liver disease for 4 years. Hepatol Res. 2013;43:979-983. [PMID: 23294411 DOI: 10.1111/hepr.12039] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
251 Lang S, Martin A, Farowski F, Wisplinghoff H, Vehreschild MJGT, Liu J, Krawczyk M, Nowag A, Kretzschmar A, Herweg J, Schnabl B, Tu XM, Lammert F, Goeser T, Tacke F, Heinzer K, Kasper P, Steffen HM, Demir M. High Protein Intake Is Associated With Histological Disease Activity in Patients With NAFLD. Hepatol Commun 2020;4:681-95. [PMID: 32363319 DOI: 10.1002/hep4.1509] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
252 Younossi ZM, Stepanova M, Rafiq N, Henry L, Loomba R, Makhlouf H, Goodman Z. Nonalcoholic steatofibrosis independently predicts mortality in nonalcoholic fatty liver disease. Hepatol Commun 2017;1:421-8. [PMID: 29404470 DOI: 10.1002/hep4.1054] [Cited by in Crossref: 60] [Cited by in F6Publishing: 50] [Article Influence: 15.0] [Reference Citation Analysis]
253 Kleiner DE, Makhlouf HR. Histology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in Adults and Children. Clin Liver Dis 2016;20:293-312. [PMID: 27063270 DOI: 10.1016/j.cld.2015.10.011] [Cited by in Crossref: 111] [Cited by in F6Publishing: 87] [Article Influence: 18.5] [Reference Citation Analysis]
254 Tarantino G. Is Assessing the Presence of NASH by Liver Histology or Surrogate Markers Always Advisable? Hepat Mon. 2013;13:e7560. [PMID: 23610586 DOI: 10.5812/hepatmon.7560] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
255 Koot BGP, Nobili V. Screening for non-alcoholic fatty liver disease in children: do guidelines provide enough guidance? Obes Rev 2017;18:1050-60. [PMID: 28544608 DOI: 10.1111/obr.12556] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
256 Kikuchi M, Ushida Y, Shiozawa H, Umeda R, Tsuruya K, Aoki Y, Suganuma H, Nishizaki Y. Sulforaphane-rich broccoli sprout extract improves hepatic abnormalities in male subjects. World J Gastroenterol. 2015;21:12457-12467. [PMID: 26604653 DOI: 10.3748/wjg.v21.i43.12457] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 28] [Article Influence: 9.0] [Reference Citation Analysis]
257 Noureddin N, Noureddin M, Singh A, Alkhouri N. Progression of Nonalcoholic Fatty Liver Disease-Associated Fibrosis in a Large Cohort of Patients with Type 2 Diabetes. Dig Dis Sci 2021. [PMID: 33779880 DOI: 10.1007/s10620-021-06955-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
258 Petta S, Amato MC, Di Marco V, Cammà C, Pizzolanti G, Barcellona MR, Cabibi D, Galluzzo A, Sinagra D, Giordano C. Visceral adiposity index is associated with significant fibrosis in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2012;35:238-247. [PMID: 22117531 DOI: 10.1111/j.1365-2036.2011.04929.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 60] [Article Influence: 6.5] [Reference Citation Analysis]
259 Holterman A, Gurria J, Tanpure S, Disomma N. Nonalcoholic fatty liver disease and bariatric surgery in adolescents. Seminars in Pediatric Surgery 2014;23:49-57. [DOI: 10.1053/j.sempedsurg.2013.10.016] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
260 Machado MV, Cortez-Pinto H. Non-alcoholic fatty liver disease: what the clinician needs to know. World J Gastroenterol. 2014;20:12956-12980. [PMID: 25278691 DOI: 10.3748/wjg.v20.i36.12956] [Cited by in CrossRef: 104] [Cited by in F6Publishing: 85] [Article Influence: 17.3] [Reference Citation Analysis]
261 Danford CJ, Connelly MA, Shalaurova I, Kim M, Herman MA, Nasser I, Otvos JD, Afdhal NH, Jiang ZG, Lai M. A Pathophysiologic Approach Combining Genetics and Insulin Resistance to Predict the Severity of Nonalcoholic Fatty Liver Disease. Hepatol Commun 2018;2:1467-78. [PMID: 30556036 DOI: 10.1002/hep4.1267] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
262 Zoller H, Tilg H. Nonalcoholic fatty liver disease and hepatocellular carcinoma. Metabolism 2016;65:1151-60. [DOI: 10.1016/j.metabol.2016.01.010] [Cited by in Crossref: 84] [Cited by in F6Publishing: 82] [Article Influence: 16.8] [Reference Citation Analysis]
263 Farrell GC, Wong VW, Chitturi S. NAFLD in Asia--as common and important as in the West. Nat Rev Gastroenterol Hepatol. 2013;10:307-318. [PMID: 23458891 DOI: 10.1038/nrgastro.2013.34] [Cited by in Crossref: 278] [Cited by in F6Publishing: 247] [Article Influence: 34.8] [Reference Citation Analysis]
264 Karlas T, Wiegand J, Berg T. Gastrointestinal complications of obesity: non-alcoholic fatty liver disease (NAFLD) and its sequelae. Best Pract Res Clin Endocrinol Metab. 2013;27:195-208. [PMID: 23731881 DOI: 10.1016/j.beem.2013.02.002] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 6.1] [Reference Citation Analysis]
265 Ballestri S, Nascimbeni F, Romagnoli D, Baldelli E, Lonardo A. The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans. Adv Ther 2016;33:291-319. [DOI: 10.1007/s12325-016-0306-9] [Cited by in Crossref: 53] [Cited by in F6Publishing: 44] [Article Influence: 10.6] [Reference Citation Analysis]
266 Wong VW, Chan RS, Wong GL, Cheung BH, Chu WC, Yeung DK, Chim AM, Lai JW, Li LS, Sea MM, Chan FK, Sung JJ, Woo J, Chan HL. Community-based lifestyle modification programme for non-alcoholic fatty liver disease: a randomized controlled trial. J Hepatol. 2013;59:536-542. [PMID: 23623998 DOI: 10.1016/j.jhep.2013.04.013] [Cited by in Crossref: 154] [Cited by in F6Publishing: 143] [Article Influence: 19.3] [Reference Citation Analysis]
267 Sabath E, Báez-Ruiz A, Buijs RM. Non-alcoholic fatty liver disease as a consequence of autonomic imbalance and circadian desynchronization. Obes Rev. 2015; Jul 27. [Epub ahead of print]. [PMID: 26214605 DOI: 10.1111/obr.12308] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
268 Kumar R. Hard clinical outcomes in patients with NAFLD. Hepatol Int 2013;7 Suppl 2:790-9. [PMID: 26202293 DOI: 10.1007/s12072-013-9455-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
269 Spengler EK, Loomba R. Recommendations for Diagnosis, Referral for Liver Biopsy, and Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Mayo Clin Proc 2015;90:1233-46. [PMID: 26219858 DOI: 10.1016/j.mayocp.2015.06.013] [Cited by in Crossref: 127] [Cited by in F6Publishing: 103] [Article Influence: 21.2] [Reference Citation Analysis]
270 European Association for Study of Liver. Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63:237-264. [PMID: 25911335 DOI: 10.1016/j.jhep.2015.04.006] [Cited by in Crossref: 918] [Cited by in F6Publishing: 731] [Article Influence: 153.0] [Reference Citation Analysis]
271 Tang R, Liu H, Yuan Y, Xie K, Xu P, Liu X, Wen J. Genetic factors associated with risk of metabolic syndrome and hepatocellular carcinoma. Oncotarget 2017;8:35403-11. [PMID: 28515345 DOI: 10.18632/oncotarget.15893] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
272 Wong GL, Chan HL, Choi PC, Chan AW, Lo AO, Chim AM, Wong VW. Association between anthropometric parameters and measurements of liver stiffness by transient elastography. Clin Gastroenterol Hepatol 2013;11:295-302.e1-3. [PMID: 23022698 DOI: 10.1016/j.cgh.2012.09.025] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 4.4] [Reference Citation Analysis]
273 Albhaisi S, Sanyal A. Recent advances in understanding and managing non-alcoholic fatty liver disease. F1000Res 2018;7:F1000 Faculty Rev-720. [PMID: 29946426 DOI: 10.12688/f1000research.14421.1] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 8.0] [Reference Citation Analysis]
274 Anstee QM, Reeves HL, Kotsiliti E, Govaere O, Heikenwalder M. From NASH to HCC: current concepts and future challenges. Nat Rev Gastroenterol Hepatol. 2019;16:411-428. [PMID: 31028350 DOI: 10.1038/s41575-019-0145-7] [Cited by in Crossref: 268] [Cited by in F6Publishing: 241] [Article Influence: 134.0] [Reference Citation Analysis]
275 Wong GL. Transient elastography: Kill two birds with one stone? World J Hepatol 2013;5:264-74. [PMID: 23717737 DOI: 10.4254/wjh.v5.i5.264] [Cited by in Crossref: 59] [Cited by in F6Publishing: 58] [Article Influence: 7.4] [Reference Citation Analysis]
276 Chow JC, Wong GL, Chan AW, Shu SS, Chan CK, Leung JK, Choi PC, Chim AM, Chan HL, Wong VW. Repeating measurements by transient elastography in non-alcoholic fatty liver disease patients with high liver stiffness: Repeating liver stiffness measurements. Journal of Gastroenterology and Hepatology 2019;34:241-8. [DOI: 10.1111/jgh.14311] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 6.3] [Reference Citation Analysis]
277 Paik JM, Golabi P, Younossi Y, Mishra A, Younossi ZM. Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD. Hepatology. 2020;72:1605-1616. [PMID: 32043613 DOI: 10.1002/hep.31173] [Cited by in Crossref: 69] [Cited by in F6Publishing: 56] [Article Influence: 69.0] [Reference Citation Analysis]
278 Sharma M, Mitnala S, Vishnubhotla RK, Mukherjee R, Reddy DN, Rao PN. The Riddle of Nonalcoholic Fatty Liver Disease: Progression From Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis. J Clin Exp Hepatol. 2015;5:147-158. [PMID: 26155043 DOI: 10.1016/j.jceh.2015.02.002] [Cited by in Crossref: 70] [Cited by in F6Publishing: 60] [Article Influence: 11.7] [Reference Citation Analysis]
279 Fabrellas N, Hernández R, Graupera I, Solà E, Ramos P, Martín N, Sáez G, Simón C, Pérez A, Graell T, Larrañaga A, Garcia M, de la Arada A, Juanola A, Coiduras A, Duaso I, Casado A, Martin J, Ginès M, Moreno N, Gema Perez A, Marti L, Bernat M, Sola M, Olivé C, Solé C, Ginès P. Prevalence of hepatic steatosis as assessed by controlled attenuation parameter (CAP) in subjects with metabolic risk factors in primary care. A population-based study. PLoS One 2018;13:e0200656. [PMID: 30226889 DOI: 10.1371/journal.pone.0200656] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
280 Ching-Yeung Yu B, Kwok D, Wong VW. Magnitude of Nonalcoholic Fatty Liver Disease: Eastern Perspective. J Clin Exp Hepatol 2019;9:491-6. [PMID: 31516265 DOI: 10.1016/j.jceh.2019.01.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
281 Noureddin M, Anstee QM, Loomba R. Review article: emerging anti-fibrotic therapies in the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2016;43:1109-23. [PMID: 27061197 DOI: 10.1111/apt.13620] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 6.8] [Reference Citation Analysis]
282 Strey CBM, de Carli LA, Fantinelli M, Gobbato SS, Bassols GF, Losekann A, Coral GP. Impact of Diabetes Mellitus and Insulin on Nonalcoholic Fatty Liver Disease in the Morbidly Obese. Ann Hepatol 2018;17:585-91. [PMID: 29893699 DOI: 10.5604/01.3001.0012.0922] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
283 Du Y, Paglicawan L, Soomro S, Abunofal O, Baig S, Vanarsa K, Hicks J, Mohan C. Epigallocatechin-3-Gallate Dampens Non-Alcoholic Fatty Liver by Modulating Liver Function, Lipid Profile and Macrophage Polarization. Nutrients 2021;13:599. [PMID: 33670347 DOI: 10.3390/nu13020599] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
284 Ganz M, Bukong TN, Csak T, Saha B, Park JK, Ambade A, Kodys K, Szabo G. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice. J Transl Med 2015;13:193. [PMID: 26077675 DOI: 10.1186/s12967-015-0552-7] [Cited by in Crossref: 72] [Cited by in F6Publishing: 63] [Article Influence: 12.0] [Reference Citation Analysis]
285 Nakamura A, Terauchi Y. Lessons from mouse models of high-fat diet-induced NAFLD. Int J Mol Sci. 2013;14:21240-21257. [PMID: 24284392 DOI: 10.3390/ijms141121240] [Cited by in Crossref: 102] [Cited by in F6Publishing: 92] [Article Influence: 12.8] [Reference Citation Analysis]
286 Drinda S, Grundler F, Neumann T, Lehmann T, Steckhan N, Michalsen A, Wilhelmi de Toledo F. Effects of Periodic Fasting on Fatty Liver Index-A Prospective Observational Study. Nutrients 2019;11:E2601. [PMID: 31671589 DOI: 10.3390/nu11112601] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 12.5] [Reference Citation Analysis]
287 Wong VW, Tse CH, Lam TT, Wong GL, Chim AM, Chu WC, Yeung DK, Law PT, Kwan HS, Yu J, Sung JJ, Chan HL. Molecular characterization of the fecal microbiota in patients with nonalcoholic steatohepatitis--a longitudinal study. PLoS One. 2013;8:e62885. [PMID: 23638162 DOI: 10.1371/journal.pone.0062885] [Cited by in Crossref: 166] [Cited by in F6Publishing: 149] [Article Influence: 20.8] [Reference Citation Analysis]
288 Bhatia LS, Curzen NP, Byrne CD. Nonalcoholic fatty liver disease and vascular risk. Curr Opin Cardiol. 2012;27:420-428. [PMID: 22596186 DOI: 10.1097/hco.0b013e328354829c] [Cited by in Crossref: 36] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
289 Falleti E, Cussigh A, Cmet S, Fabris C, Toniutto P. PNPLA3 rs738409 and TM6SF2 rs58542926 variants increase the risk of hepatocellular carcinoma in alcoholic cirrhosis. Dig Liver Dis. 2016;48:69-75. [PMID: 26493626 DOI: 10.1016/j.dld.2015.09.009] [Cited by in Crossref: 49] [Cited by in F6Publishing: 43] [Article Influence: 8.2] [Reference Citation Analysis]
290 Gluchowski NL, Gabriel KR, Chitraju C, Bronson RT, Mejhert N, Boland S, Wang K, Lai ZW, Farese RV Jr, Walther TC. Hepatocyte Deletion of Triglyceride-Synthesis Enzyme Acyl CoA: Diacylglycerol Acyltransferase 2 Reduces Steatosis Without Increasing Inflammation or Fibrosis in Mice. Hepatology 2019;70:1972-85. [PMID: 31081165 DOI: 10.1002/hep.30765] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 11.5] [Reference Citation Analysis]
291 Tziomalos K, Giampatzis V, Bouziana SD, Spanou M, Papadopoulou M, Pavlidis A, Kostaki S, Bozikas A, Savopoulos C, Hatzitolios AI. Association between nonalcoholic fatty liver disease and acute ischemic stroke severity and outcome. World J Hepatol. 2013;5:621-626. [PMID: 24303090 DOI: 10.4254/wjh.v5.i11.621] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
292 Bower G, Athanasiou T, Isla AM, Harling L, Li JV, Holmes E, Efthimiou E, Darzi A, Ashrafian H. Bariatric surgery and nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2015;27:755-768. [PMID: 25919774 DOI: 10.1097/meg.0000000000000375] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 3.6] [Reference Citation Analysis]
293 Muthiah MD, Sanyal AJ. Burden of Disease due to Nonalcoholic Fatty Liver Disease. Gastroenterol Clin North Am 2020;49:1-23. [PMID: 32033757 DOI: 10.1016/j.gtc.2019.09.007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 13.0] [Reference Citation Analysis]
294 Noureddin M, Sanyal AJ. Pathogenesis of NASH: The Impact of Multiple Pathways. Curr Hepatol Rep 2018;17:350-60. [PMID: 31380156 DOI: 10.1007/s11901-018-0425-7] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 9.3] [Reference Citation Analysis]
295 Shen J, Chan HL, Wong GL, Choi PC, Chan AW, Chan HY, Chim AM, Yeung DK, Chan FK, Woo J, Yu J, Chu WC, Wong VW. Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers. J Hepatol. 2012;56:1363-1370. [PMID: 22314419 DOI: 10.1016/j.jhep.2011.12.025] [Cited by in Crossref: 141] [Cited by in F6Publishing: 118] [Article Influence: 15.7] [Reference Citation Analysis]
296 Nascimbeni F, Ballestri S, Machado MV, Mantovani A, Cortez-pinto H, Targher G, Lonardo A. Clinical relevance of liver histopathology and different histological classifications of NASH in adults. Expert Review of Gastroenterology & Hepatology 2018;12:351-67. [DOI: 10.1080/17474124.2018.1415756] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 6.8] [Reference Citation Analysis]
297 Agrawal S, Duseja AK. Non-alcoholic Fatty Liver Disease: East Versus West. J Clin Exp Hepatol 2012;2:122-34. [PMID: 25755421 DOI: 10.1016/S0973-6883(12)60101-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
298 Gatselis NK, Ntaios G, Makaritsis K, Dalekos GN. Adiponectin: a key playmaker adipocytokine in non-alcoholic fatty liver disease. Clin Exp Med. 2014;14:121-131. [PMID: 23292294 DOI: 10.1007/s10238-012-0227-0] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 4.5] [Reference Citation Analysis]
299 Fierbinteanu-Braticevici C, Sinescu C, Moldoveanu A, Petrisor A, Diaconu S, Cretoiu D, Braticevici B. Nonalcoholic fatty liver disease: one entity, multiple impacts on liver health. Cell Biol Toxicol 2017;33:5-14. [PMID: 27680752 DOI: 10.1007/s10565-016-9361-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
300 McPherson S, Hardy T, Dufour JF, Petta S, Romero-Gomez M, Allison M, Oliveira CP, Francque S, Van Gaal L, Schattenberg JM, Tiniakos D, Burt A, Bugianesi E, Ratziu V, Day CP, Anstee QM. Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis. Am J Gastroenterol. 2017;112:740-751. [PMID: 27725647 DOI: 10.1038/ajg.2016.453] [Cited by in Crossref: 208] [Cited by in F6Publishing: 178] [Article Influence: 41.6] [Reference Citation Analysis]
301 Kwok R, Choi KC, Wong GL, Zhang Y, Chan HL, Luk AO, Shu SS, Chan AW, Yeung MW, Chan JC, Kong AP, Wong VW. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. Gut. 2016;65:1359-1368. [PMID: 25873639 DOI: 10.1136/gutjnl-2015-309265] [Cited by in Crossref: 217] [Cited by in F6Publishing: 179] [Article Influence: 36.2] [Reference Citation Analysis]
302 Gallego-Durán R, Cerro-Salido P, Gomez-Gonzalez E, Pareja MJ, Ampuero J, Rico MC, Aznar R, Vilar-Gomez E, Bugianesi E, Crespo J, González-Sánchez FJ, Aparcero R, Moreno I, Soto S, Arias-Loste MT, Abad J, Ranchal I, Andrade RJ, Calleja JL, Pastrana M, Iacono OL, Romero-Gómez M. Imaging biomarkers for steatohepatitis and fibrosis detection in non-alcoholic fatty liver disease. Sci Rep 2016;6:31421. [PMID: 27514671 DOI: 10.1038/srep31421] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
303 Wang JZ, Cao HX, Chen JN, Pan Q. PNPLA3 rs738409 underlies treatment response in nonalcoholic fatty liver disease. World J Clin Cases 2018;6:167-75. [PMID: 30148144 DOI: 10.12998/wjcc.v6.i8.167] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
304 Akuta N, Kawamura Y, Suzuki F, Saitoh S, Arase Y, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, Suzuki Y, Kobayashi M, Ikeda K, Kumada H. Analysis of association between circulating miR-122 and histopathological features of nonalcoholic fatty liver disease in patients free of hepatocellular carcinoma. BMC Gastroenterol 2016;16:141. [PMID: 27955628 DOI: 10.1186/s12876-016-0557-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
305 Sung KC, Ryu S, Lee JY, Kim JY, Wild SH, Byrne CD. Effect of exercise on the development of new fatty liver and the resolution of existing fatty liver. J Hepatol 2016;65:791-7. [PMID: 27255583 DOI: 10.1016/j.jhep.2016.05.026] [Cited by in Crossref: 60] [Cited by in F6Publishing: 45] [Article Influence: 12.0] [Reference Citation Analysis]
306 Rowe IA, Wong VW, Loomba R. Treatment Candidacy for Pharmacologic Therapies for NASH. Clinical Gastroenterology and Hepatology 2021. [DOI: 10.1016/j.cgh.2021.03.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
307 Min YW, Yun HS, Chang WI, Kim JY, Kim YH, Son HJ, Kim JJ, Rhee JC, Chang DK. Influence of non-alcoholic fatty liver disease on the prognosis in patients with colorectal cancer. Clin Res Hepatol Gastroenterol 2012;36:78-83. [PMID: 22133576 DOI: 10.1016/j.clinre.2011.10.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
308 Lazo M, Hernaez R, Eberhardt MS, Bonekamp S, Kamel I, Guallar E, Koteish A, Brancati FL, Clark JM. Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol 2013;178:38-45. [PMID: 23703888 DOI: 10.1093/aje/kws448] [Cited by in Crossref: 506] [Cited by in F6Publishing: 442] [Article Influence: 63.3] [Reference Citation Analysis]
309 Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: management of nonalcoholic fatty liver disease. Clin Mol Hepatol 2013;19:325-48. [PMID: 24459637 DOI: 10.3350/cmh.2013.19.4.325] [Cited by in Crossref: 75] [Cited by in F6Publishing: 67] [Article Influence: 9.4] [Reference Citation Analysis]
310 Masuoka HC, Chalasani N. Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals. Ann N Y Acad Sci. 2013;1281:106-122. [PMID: 23363012 DOI: 10.1111/nyas.12016] [Cited by in Crossref: 159] [Cited by in F6Publishing: 134] [Article Influence: 19.9] [Reference Citation Analysis]
311 Ekstedt M, Nasr P, Kechagias S. Natural History of NAFLD/NASH. Curr Hepatol Rep. 2017;16:391-397. [PMID: 29984130 DOI: 10.1007/s11901-017-0378-2] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 12.8] [Reference Citation Analysis]
312 Itsiopoulos C, Marx W, Mayr H, Tatucu-babet O, Dash S, George E, Trakman G, Kelly J, Thomas C, Brazionis L. The role of omega-3 polyunsaturated fatty acid supplementation in the management of type 2 diabetes mellitus: A narrative review. Journal of Nutrition & Intermediary Metabolism 2018;14:42-51. [DOI: 10.1016/j.jnim.2018.02.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 5.7] [Reference Citation Analysis]
313 Lu ZY, Shao Z, Li YL, Wulasihan M, Chen XH. Prevalence of and risk factors for non-alcoholic fatty liver disease in a Chinese population: An 8-year follow-up study. World J Gastroenterol 2016;22:3663-9. [PMID: 27053858 DOI: 10.3748/wjg.v22.i13.3663] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
314 Wehmeyer MH, Zyriax BC, Jagemann B, Roth E, Windler E, Schulze Zur Wiesch J, Lohse AW, Kluwe J. Nonalcoholic fatty liver disease is associated with excessive calorie intake rather than a distinctive dietary pattern. Medicine (Baltimore) 2016;95:e3887. [PMID: 27281105 DOI: 10.1097/MD.0000000000003887] [Cited by in Crossref: 41] [Cited by in F6Publishing: 22] [Article Influence: 10.3] [Reference Citation Analysis]
315 Marcuccilli M, Chonchol M. NAFLD and Chronic Kidney Disease. Int J Mol Sci. 2016;17:562. [PMID: 27089331 DOI: 10.3390/ijms17040562] [Cited by in Crossref: 64] [Cited by in F6Publishing: 50] [Article Influence: 12.8] [Reference Citation Analysis]
316 De A, Duseja A. Natural History of Simple Steatosis or Nonalcoholic Fatty Liver. J Clin Exp Hepatol 2020;10:255-62. [PMID: 32405182 DOI: 10.1016/j.jceh.2019.09.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
317 Wong RJ, Ahmed A. Obesity and non-alcoholic fatty liver disease: Disparate associations among Asian populations. World J Hepatol. 2014;6:263-273. [PMID: 24868320 DOI: 10.4254/wjh.v6.i5.263] [Cited by in Crossref: 74] [Cited by in F6Publishing: 54] [Article Influence: 10.6] [Reference Citation Analysis]
318 Chitturi S, Wong VW, Farrell G. Nonalcoholic fatty liver in Asia: Firmly entrenched and rapidly gaining ground. J Gastroenterol Hepatol. 2011;26 Suppl 1:163-172. [PMID: 21199528 DOI: 10.1111/j.1440-1746.2010.06548.x] [Cited by in Crossref: 110] [Cited by in F6Publishing: 105] [Article Influence: 11.0] [Reference Citation Analysis]
319 Wong VW, Wong GL, Chim AM, Chu WC, Yeung DK, Li KC, Chan HL. Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study. Annals of Hepatology 2013;12:256-62. [DOI: 10.1016/s1665-2681(19)31364-x] [Cited by in Crossref: 158] [Article Influence: 19.8] [Reference Citation Analysis]
320 Reddy YK, Marella HK, Jiang Y, Ganguli S, Snell P, Podila PSB, Maliakkal B, Satapathy SK. Natural History of Non-Alcoholic Fatty Liver Disease: A Study With Paired Liver Biopsies. J Clin Exp Hepatol. 2020;10:245-254. [PMID: 32405181 DOI: 10.1016/j.jceh.2019.07.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
321 Zhang E, Wartelle-Bladou C, Lepanto L, Lachaine J, Cloutier G, Tang A. Cost-utility analysis of nonalcoholic steatohepatitis screening. Eur Radiol. 2015;25:3282-3294. [PMID: 25994191 DOI: 10.1007/s00330-015-3731-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
322 Maurantonio M, Ballestri S, Odoardi MR, Lonardo A, Loria P. Treatment of atherogenic liver based on the pathogenesis of nonalcoholic fatty liver disease: a novel approach to reduce cardiovascular risk? Arch Med Res. 2011;42:337-353. [PMID: 21843565 DOI: 10.1016/j.arcmed.2011.08.004] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
323 Mahady SE, George J. The future liver of the Asia pacific: fatter and firmer from more fructose and fortune? J Clin Exp Hepatol 2013;3:106-13. [PMID: 25755484 DOI: 10.1016/j.jceh.2012.10.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
324 Chung HS, Choi KM. Organokines in disease. Adv Clin Chem 2020;94:261-321. [PMID: 31952573 DOI: 10.1016/bs.acc.2019.07.012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
325 Fernandez ML. Lifestyle Factors and Genetic Variants Associated to Health Disparities in the Hispanic Population. Nutrients 2021;13:2189. [PMID: 34202120 DOI: 10.3390/nu13072189] [Reference Citation Analysis]
326 Chen J, Liu J, Wang Y, Hu X, Zhou F, Hu Y, Yuan Y, Xu Y. Wogonin mitigates nonalcoholic fatty liver disease via enhancing PPARα/AdipoR2, in vivo and in vitro. Biomed Pharmacother 2017;91:621-31. [PMID: 28486193 DOI: 10.1016/j.biopha.2017.04.125] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
327 Musso G, Cassader M, Olivetti C, Rosina F, Carbone G, Gambino R. Association of obstructive sleep apnoea with the presence and severity of non-alcoholic fatty liver disease. A systematic review and meta-analysis. Obes Rev. 2013;14:417-431. [PMID: 23387384 DOI: 10.1111/obr.12020] [Cited by in Crossref: 131] [Cited by in F6Publishing: 115] [Article Influence: 16.4] [Reference Citation Analysis]
328 Wong MCS, Huang JLW, George J, Huang J, Leung C, Eslam M, Chan HLY, Ng SC. The changing epidemiology of liver diseases in the Asia–Pacific region. Nat Rev Gastroenterol Hepatol 2019;16:57-73. [DOI: 10.1038/s41575-018-0055-0] [Cited by in Crossref: 86] [Cited by in F6Publishing: 70] [Article Influence: 28.7] [Reference Citation Analysis]
329 Eguchi Y, Wong G, Lee EI, Akhtar O, Lopes R, Sumida Y. Epidemiology of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Japan: A focused literature review. JGH Open 2020;4:808-17. [PMID: 33102749 DOI: 10.1002/jgh3.12349] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
330 Zelber-sagi S, Toker S, Armon G, Melamed S, Berliner S, Shapira I, Halpern Z, Santo E, Shibolet O. Elevated alanine aminotransferase independently predicts new onset of depression in employees undergoing health screening examinations. Psychol Med 2013;43:2603-13. [DOI: 10.1017/s0033291713000500] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
331 Ter Horst KW, Serlie MJ. Fructose Consumption, Lipogenesis, and Non-Alcoholic Fatty Liver Disease. Nutrients. 2017;9. [PMID: 28878197 DOI: 10.3390/nu9090981] [Cited by in Crossref: 79] [Cited by in F6Publishing: 71] [Article Influence: 19.8] [Reference Citation Analysis]
332 Liu CJ. Prevalence and risk factors for non-alcoholic fatty liver disease in Asian people who are not obese. J Gastroenterol Hepatol. 2012;27:1555-1560. [PMID: 22741595 DOI: 10.1111/j.1440-1746.2012.07222.x] [Cited by in Crossref: 117] [Cited by in F6Publishing: 114] [Article Influence: 14.6] [Reference Citation Analysis]
333 Meneses MJ, Silvestre R, Sousa-Lima I, Macedo MP. Paraoxonase-1 as a Regulator of Glucose and Lipid Homeostasis: Impact on the Onset and Progression of Metabolic Disorders. Int J Mol Sci 2019;20:E4049. [PMID: 31430977 DOI: 10.3390/ijms20164049] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 10.5] [Reference Citation Analysis]
334 Lavallard VJ, Bonnafous S, Patouraux S, Saint-Paul MC, Rousseau D, Anty R, Le Marchand-Brustel Y, Tran A, Gual P. Serum markers of hepatocyte death and apoptosis are non invasive biomarkers of severe fibrosis in patients with alcoholic liver disease. PLoS One. 2011;6:e17599. [PMID: 21445263 DOI: 10.1371/journal.pone.0017599] [Cited by in Crossref: 45] [Cited by in F6Publishing: 36] [Article Influence: 4.5] [Reference Citation Analysis]
335 Magee N, Zou A, Ghosh P, Ahamed F, Delker D, Zhang Y. Disruption of hepatic small heterodimer partner induces dissociation of steatosis and inflammation in experimental nonalcoholic steatohepatitis. J Biol Chem 2020;295:994-1008. [PMID: 31831621 DOI: 10.1074/jbc.RA119.010233] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
336 Ha Y, Seo N, Shim JH, Kim SY, Park JA, Han S, Kim KW, Yu E, Kim KM, Lim YS, Lee HC, Chung YH, Lee YS. Intimate association of visceral obesity with non-alcoholic fatty liver disease in healthy Asians: A case-control study. J Gastroenterol Hepatol. 2015;30:1666-1672. [PMID: 25974139 DOI: 10.1111/jgh.12996] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
337 Bekaert M, Ouwens DM, Hörbelt T, Van de Velde F, Fahlbusch P, Herzfeld de Wiza D, Van Nieuwenhove Y, Calders P, Praet M, Hoorens A, Geerts A, Verhelst X, Kaufman J, Lapauw B. Reduced expression of chemerin in visceral adipose tissue associates with hepatic steatosis in patients with obesity: Chemerin Expression in Patients with NAFLD. Obesity 2016;24:2544-52. [DOI: 10.1002/oby.21674] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
338 Lee CH, Fu Y, Yang SJ, Chi CC. Effects of Omega-3 Polyunsaturated Fatty Acid Supplementation on Non-Alcoholic Fatty Liver: A Systematic Review and Meta-Analysis. Nutrients 2020;12:E2769. [PMID: 32932796 DOI: 10.3390/nu12092769] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
339 Kim Y, Chang Y, Cho YK, Ahn J, Shin H, Ryu S. Obesity and Weight Gain Are Associated With Progression of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol 2019;17:543-550.e2. [PMID: 30012432 DOI: 10.1016/j.cgh.2018.07.006] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
340 Wai-sun Wong V, Kanwal F. On the Proposed Definition of Metabolic-Associated Fatty Liver Disease. Clinical Gastroenterology and Hepatology 2021;19:865-70. [DOI: 10.1016/j.cgh.2021.01.017] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 10.0] [Reference Citation Analysis]
341 Saiman Y, Hooks R, Carr RM. High-Risk Groups for Non-alcoholic Fatty Liver and Non-alcoholic Steatohepatitis Development and Progression. Curr Hepatology Rep 2020;19:412-9. [DOI: 10.1007/s11901-020-00539-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
342 Huang JF, Yeh ML, Yu ML, Huang CF, Dai CY, Hsieh MY, Hsieh MH, Huang CI, Lin ZY, Chen SC, Hsiao PJ, Shin SJ, Chuang WL. Hyperuricemia Inversely Correlates with Disease Severity in Taiwanese Nonalcoholic Steatohepatitis Patients. PLoS One 2015;10:e0139796. [PMID: 26441244 DOI: 10.1371/journal.pone.0139796] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
343 Kim TH, Jeong CW, Jun HY, Lee C, Noh S, Kim JE, Kim S, Yoon KH. Accuracy of proton magnetic resonance for diagnosing non-alcoholic steatohepatitis: a meta-analysis. Sci Rep 2019;9:15002. [PMID: 31628409 DOI: 10.1038/s41598-019-51302-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
344 Bantel H, John K, Schulze-osthoff K. Robust Detection of Liver Steatosis and Staging of NAFLD by an Improved ELISA for Serum Cytokeratin-18 Fragments. American Journal of Gastroenterology 2014;109:140-1. [DOI: 10.1038/ajg.2013.350] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
345 García-compeán D, Villarreal-pérez JZ, Cavazos MEDLO, Lavalle-gonzalez FJ, Borjas-almaguer OD, Del Cueto-aguilera AN, González-gonzález JA, Treviño-garza C, Huerta-pérez L, Maldonado-garza HJ. Prevalence of liver fibrosis in an unselected general population with high prevalence of obesity and diabetes mellitus. Time for screening? Annals of Hepatology 2020;19:258-64. [DOI: 10.1016/j.aohep.2020.01.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
346 Nati M, Haddad D, Birkenfeld AL, Koch CA, Chavakis T, Chatzigeorgiou A. The role of immune cells in metabolism-related liver inflammation and development of non-alcoholic steatohepatitis (NASH). Rev Endocr Metab Disord. 2016;17:29-39. [PMID: 26847547 DOI: 10.1007/s11154-016-9339-2] [Cited by in Crossref: 64] [Cited by in F6Publishing: 62] [Article Influence: 16.0] [Reference Citation Analysis]
347 Paz-Filho G, Mastronardi CA, Parker BJ, Khan A, Inserra A, Matthaei KI, Ehrhart-Bornstein M, Bornstein S, Wong ML, Licinio J. Molecular pathways involved in the improvement of non-alcoholic fatty liver disease. J Mol Endocrinol 2013;51:167-79. [PMID: 23718963 DOI: 10.1530/JME-13-0072] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
348 Petta S, Ting J, Saragoni S, Degli Esposti L, Shreay S, Petroni ML, Marchesini G. Healthcare resource utilization and costs of nonalcoholic steatohepatitis patients with advanced liver disease in Italy. Nutrition, Metabolism and Cardiovascular Diseases 2020;30:1014-22. [DOI: 10.1016/j.numecd.2020.02.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
349 Benedict M, Zhang X. Non-alcoholic fatty liver disease: An expanded review. World J Hepatol. 2017;9:715-732. [PMID: 28652891 DOI: 10.4254/wjh.v9.i16.715] [Cited by in Crossref: 290] [Cited by in F6Publishing: 230] [Article Influence: 72.5] [Reference Citation Analysis]
350 Arteaga I, Buezo I, Expósito C, Pera G, Rodríguez L, Alumà A, Auladell MA, Torán P, Caballería L. [Non-invasive markers of fibrosis in the diagnosis of non-alcoholic fatty liver disease]. Gastroenterol Hepatol 2014;37:503-10. [PMID: 24746708 DOI: 10.1016/j.gastrohep.2014.03.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
351 Calzadilla Bertot L, Adams LA. The Natural Course of Non-Alcoholic Fatty Liver Disease. Int J Mol Sci. 2016;17. [PMID: 27213358 DOI: 10.3390/ijms17050774] [Cited by in Crossref: 248] [Cited by in F6Publishing: 217] [Article Influence: 49.6] [Reference Citation Analysis]
352 Roulot D, Roudot-thoraval F, Nkontchou G, Kouacou N, Costes J, Elourimi G, Le Clesiau H, Ziol M, Beaugrand M. Concomitant screening for liver fibrosis and steatosis in French type 2 diabetic patients using Fibroscan. Liver Int 2017;37:1897-906. [DOI: 10.1111/liv.13481] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 9.5] [Reference Citation Analysis]
353 Kawanaka M, Nouso K, Yano S, Nakamura J, Nishino K, Suehiro M, Kawamoto H. Case report of diet-related improvements of non-alcoholic steatohepatitis evaluated by four consecutive liver biopsies. Hepatol Res 2017;47:480-4. [PMID: 27355753 DOI: 10.1111/hepr.12768] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
354 Paredes AH, Torres DM, Harrison SA. Nonalcoholic Fatty Liver Disease. Clinics in Liver Disease 2012;16:397-419. [DOI: 10.1016/j.cld.2012.03.005] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 5.4] [Reference Citation Analysis]
355 Zelber-Sagi S, Webb M, Assy N, Blendis L, Yeshua H, Leshno M, Ratziu V, Halpern Z, Oren R, Santo E. Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification. World J Gastroenterol 2013;19:57-64. [PMID: 23326163 DOI: 10.3748/wjg.v19.i1.57] [Cited by in CrossRef: 67] [Cited by in F6Publishing: 56] [Article Influence: 8.4] [Reference Citation Analysis]
356 Wong VW, Chan WK, Chitturi S, Chawla Y, Dan YY, Duseja A, Fan J, Goh KL, Hamaguchi M, Hashimoto E, Kim SU, Lesmana LA, Lin YC, Liu CJ, Ni YH, Sollano J, Wong SK, Wong GL, Chan HL, Farrell G. Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 1: Definition, risk factors and assessment. J Gastroenterol Hepatol. 2018;33:70-85. [PMID: 28670712 DOI: 10.1111/jgh.13857] [Cited by in Crossref: 165] [Cited by in F6Publishing: 137] [Article Influence: 82.5] [Reference Citation Analysis]
357 Barata L, Feitosa MF, Bielak LF, Halligan B, Baldridge AS, Guo X, Yerges-Armstrong LM, Smith AV, Yao J, Palmer ND, VanWagner LB, Carr JJ, Chen YI, Allison M, Budoff MJ, Handelman SK, Kardia SLR, Mosley TH Jr, Ryan K, Harris TB, Launer LJ, Gudnason V, Rotter JI, Fornage M, Rasmussen-Torvik LJ, Borecki IB, O'Connell JR, Peyser PA, Speliotes EK, Province MA. Insulin Resistance Exacerbates Genetic Predisposition to Nonalcoholic Fatty Liver Disease in Individuals Without Diabetes. Hepatol Commun 2019;3:894-907. [PMID: 31334442 DOI: 10.1002/hep4.1353] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
358 Kim YS, Jung ES, Hur W, Bae SH, Choi JY, Song MJ, Kim CW, Jo SH, Lee CD, Lee YS, Choi SW, Yang JM, Jang JW, Kim SG, Jung SW, Kim HK, Chae HB, Yoon SK. Noninvasive predictors of nonalcoholic steatohepatitis in Korean patients with histologically proven nonalcoholic fatty liver disease. Clin Mol Hepatol 2013;19:120-30. [PMID: 23837136 DOI: 10.3350/cmh.2013.19.2.120] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
359 Byrne CD, Targher G. Time to Replace Assessment of Liver Histology With MR-Based Imaging Tests to Assess Efficacy of Interventions for Nonalcoholic Fatty Liver Disease. Gastroenterology 2016;150:7-10. [DOI: 10.1053/j.gastro.2015.11.016] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 5.2] [Reference Citation Analysis]
360 Cheuk-fung Yip T, Wai-sun Wong V, Lik-yuen Chan H, Tse Y, Pik-shan Kong A, Long-yan Lam K, Chung-yan Lui G, Lai-hung Wong G. Effects of Diabetes and Glycemic Control on Risk of Hepatocellular Carcinoma After Seroclearance of Hepatitis B Surface Antigen. Clinical Gastroenterology and Hepatology 2018;16:765-773.e2. [DOI: 10.1016/j.cgh.2017.12.009] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 6.7] [Reference Citation Analysis]